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OBJECTIVE:  
To assess the feasibility of modelling Bone Marrow Sparing IMRT without compromising the 
dose to the planning target volume and without increasing the dose to other organs at risk. 
METHODS:CT Data set from 16 women with Carcinoma cervix treated in our institution from 
July 2013 to January 2014 using 3D CRT or IMRT were selected for the study. For all  the 16 
patients ,4 plans ;four field box,3DCRT, IMRT and Bone Marrow Sparing IMRT were 
modeled.Bone marrow was contoured using free hand technique in each CT cut including entire 
L5 vertebral body, sacrum, coccyx, ileum, ischium, pubis and femoral head extending down till 
the level of ischial tuberosity. Constraints to the organs at risk and the target volume were 
prescribed as per the standard RTOG guidelines.Bone Marrow constrain was V10< 95% and V 
20< 76%.Dose volume histogram,isodose curves, dose colour wash and presence of hot spot 
were used for plan evaluation. Chi-square test was used for statistical analysis. 
RESULTS 
Out of the 16 plans with BMS IMRT, 15 plans achieved the desired goals while respecting the 
bone marrow constrains. This gave a 93.8% chance of  achieving this constrain with a p value of 
.001.The The mean V10 and V20 to bone marrowin our study was 89.58% and 69.99%. In case 
of femoral head, it was observed that the constrain was attained for 12/16 patients with 4 FIELD 
BOX, 12/16 patients for 3DCRT, 16/16 patients with IMRT and 16/16 patients with BMS –
IMRT.The bowel bag constrain could be achieved for 13/16 patients with 4 FIELD BOX plan, 
12/16 patients with 3DCRT plan, 16/16 patients with IMRT plan an 16/16 patients with BMS –
IMRT plan .Bladder and rectum constrains could not be achieved in any of the plans. 
Bone Marrow Sparing IMRT is a feasible option for the management of locally advanced 
carcinoma cervix as it helps in reducing the dose received by the bone marrow without 
compromising the planning target volume coverage and without increasing the dose to other 
normal organs at risk. 
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1. INTRODUCTION: 
 
Carcinoma cervix is one among the leading causes of cancer related deaths among women in 
developing countries like India. Majority of these patients present with locally advanced 
disease. The current standard of management for locally advanced carcinoma cervix is 
concurrent chemotherapy and radiation therapy.While this combination has significant 
survival benefit, it is often associated with severe haematological toxicity.One of the key 
reasons for haematological toxicity is significant dose to bone marrow of the pelvis .Over the 
years treatment techniques have evolved and it is now possible to precisely target the tumor 
and avoid the normal structures.However these techniques are unable to decrease the dose to 
bone marrow in a significant way.IMRT is one of such techniques which can achieve 
conformity to the target while respecting the dose constraints to organs at risk and can 
potentially decrease the dose to the bone marrow. 
This study was undertaken to evaluate whether Bone marrow Sparing IMRT plan 
significantly reduce the dose to the bone marrow without compromising planning  target dose 
coverage and without increasing the dose to other organs at risk. 
2.AIM 
Dosimetric comparison between Bone marrow sparing Intensity modulated radiotherapy 
(BMS IMRT ) ,  Intensity modulated radiotherapy ( IMRT ), Three dimensional conformal 
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radiation therapy ( 3D CRT ) and Conventional four field box technique in the treatment of 
carcinoma cervix and evaluate its role in sparing bone marrow . 
3.OBJECTIVES 
 
1. Comparison of V10 and V20 of bone marrow in carcinoma cervix patients with BMS 
IMRT , IMRT , 3D CRT and four field box technique 
2. Comparison of dose volume sparing effect on other normal pelvic organs  
3. Comparison of dose coverage to the planning target volume 
4. LITERATURE REVIEW 
 
 
4.1 CANCER STATISTICS: 
 
 As per the latest world cancer statistics by the International Agency for Research on Cancer 
(IARC), the global cancer burden has risento 14.1 millionfrom 12.7 million new cancer cases 
and cancerdeaths rises from 7.6 million to 8.2 million from 2008 to  2012 . With more than 5 
lakhincident cases peryear, cervical cancer is currently the fourth most common cancer 
affecting women worldwide. According to the SEER Data base in US, the incidence rate of 
cervical cancer  was found to be 7.9 per 1 lakh women per year for all the races and 6.6 per 1 
lakh women for Asia and Pacific region(1). 
 
In case of carcinoma cervix, approximately 70% of the cases are reported from  developing 
countries(1).Among the developing countries, one fifth of new cases are diagnosed in 
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India.The reasons for this can be mainly attributed to the etiological factors, low 
socioeconomic status and lack of screening programs. 
 
In India the most common malignancy that affects women is carcinoma cervix and most of 
our patients present with advance disease.As per the various cancer registries during the year 
1990-1997, the  cervical cancer incidence was found to be varying  from 10.9 to 65.4(2). 
According to the ICMR-Population based cancer registry-Chennai, in Chennai the relative 
proportion of cervical cancer is found to be 18.5 % of all cancers in females, with crude ratio 
of 20.3 and age adjusted ratio of 22.3 incidence rate per 1 lakh person(3). 
4.2 ANATOMY: 
 
 
 Fig 1.1: Anatomy of the Uterine Cervix 
Uterus is a hollow,pear shaped; muscular organ usually in an anteverted position, located in 
the pelvis. It is bounded anteriorly by the urinary bladder and posteriorly by rectum. It is 
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covered by the peritoneum partially at the fundus and posterior aspect. The inferior most part 
of the uterus is called uterine cervix .The cervix measures approximately 3 cm in length and 3 
cm in breadth. It is mainly a fibrous organ. The cervix itself is divided into a supravaginal 
portion which is above the vagina and vaginal portion which protrudes into the vagina.
 
 
 Fig 1.2: Uterus and Adnexa 
Uterus is attached to the surrounding structures in the pelvis by means of two ligaments, 
broad ligament and the round ligament. The broad ligament is composed of two layers of 
peritoneum.It extends from the lateral pelvic wall to the lateral margin of the uterus.It 
encloses the parametrium as it reaches the uterus.It contains the fallopian tube. The broad 
ligament follows the plane of pelvic floor inferiorly and ends in the upper portion of the 
vagina medially. 
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The round ligament is a band of smooth muscle and connective tissue .It contains small 
vessels and nerves. It extends horizontally from its attachment in the Anterolateral aspect of 
the uterus to the lateral pelvic wall. From there the cord ascends, reaches more laterally to 
reach the abdominoinguinal ring through which it leaves the abdomen to traverse the inguinal 
canal and terminates in the superficial fascia. 
 
The utero sacral ligaments are paired supports for the lower uterus. It runs along the recto-
uterine-peritoneal fields connecting uterus to the sacrum. The cardinal ligament, otherwise 
named as the transverse cervical ligament or Mackenrodt`s ligament arises from the upper 
lateral margins of the cervix and insert into the fascia covering the pelvic diaphragm. 
 
Lymphatic supply: Uterine cervix has a rich lymphatic supply that drains mainly into the 
paracervical lymphnodes.From there it drains into the external iliac lymphnodes and the hypo 
gastric lymph nodes.Finally the pelvic lymph nodes drain into the common iliac lymph nodes 
andthe Paraaortic lymph nodes. 
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Fig 1.3: Lymphatic drainage  
Lymphatics from the uterine fundus crosses laterally across the broad ligament, ascends 
along the ovarian vessels into the Paraaortic lymphatic nodes. Few other lymphatics from the 
uterine fundus region drain into the common iliac lymph nodes. 
Arterial Supply: The main arterial supply is by the uterine artery which originates from the 
anterior division of the hypo gastric artery. 
19 
 
 
Fig.1.4:Arterial Supply of Uterus and cervix 
 
4.3 EPIDEMIOLOGY: 
 
Cervical cancer is the most common gynaecological cancer. It often affects young women 
and has a significant socio-economic impact on the society. In developing countries like India 
carcinoma of the cervix cause is the leading for cancer related death(4).It is more common in 
area where there is less access to cancer screening programs.  
 
There are many known and unknown factors that leads to cervical cancer and cannot be 
attributed to lack of cancer screening alone.The various factors includes socio economic 
status, health care access , parity, smoking , presence of other infections , immune status and 
other factors affecting host immunity such as nutritional status. 
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HUMAN PAPILLOMA VIRUS 
 
It is indicated by various estimates that more than 90 % off the cervical cancers are related to 
human papilloma virus (HPV).It is contracted via sexual intercourse.HPV is a small double 
stranded DNA virus.HPV 16 and 18 are the most common causative agents for cervical 
cancer(5) with some with some geographical variation. 
Mechanism of action of HPV virus leading to cervical cancer:  
Once infected the genome of HPV virus integrates into the host cell chromosome in cervical 
epithelial cells. This virus genome codes for six early and two late open reading frame 
proteins. Of these three viral genes, E5, E6 and E7 alter cellular proliferation. In HPV 
positive cervical cancers two viral genes E6 and E7 are typically expressed.E6 protein 
inactivates the tumour suppressor gene p53 hence resulting in chromosomal instability(6), 
inhibition of apoptosis and activation of telomerase.The E7 protein affects the retinoblastoma 
protein (Rb)(7) .This results in loss of regulation of cellular proliferation and immortalization. 
Peak age of prevalence of HPV infection is between 25 to 35 years of age.After getting 
infected with HPV virus less than 15 % of the exposed women gets persistent infection that 
results in dysplasia.Majority of the women get cleared of the infection within 2 
years.Cervical cancer usually develops 10 to 20 years after the initial exposure of HPV virus. 
The major social factors that results in cervical cancer including those associated with HPV 
transmission are early age of first intercourse,  more number of pregnancies , multiple sex 
partners, a male partner with history of contact with  multiple sexual partners , a history of 
sexually transmitted disease, which may include gonorrhoea, Chlamydia , herpes simplex 
virus II , and / or Human immunodeficiency virus( HIV). 
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Other causative factors implicated in cervical cancers include exposure to chemicals, 
hormones, or other carcinogens. Association of cervical cancers and usage of oral 
contraceptives is considered controversial. Prenatal exposure to diethylstilbestrol is 
associated with development of clear cell adenocarcinoma(8). But the overall incidence is 
very small. Active cigarette smoking may increase the risk of carcinoma cervix. Few reports 
have shown that the usage of intrauterine contraceptive devices may decrease the potential of 
carcinoma cervix .The mechanism is said to be increased cellular immunity triggered by the 
device. 
4.4 NATURAL HISTORY AND PATTERN OF SPREAD: 
 
Squamous cell carcinoma of the cervix usually arises from the squamo columnar junction 
which is other called as the transformation zone between the endocervical canal and the 
portion ofcervix. Once cellular transformation occurs there will be a stepwise progression 
from normal to higher levels of dysplasia. In case of the patients who are diagnosed to have 
cervical intraepithelial neoplasm (CIN) type 1, 60% have regression of lesion and in those 
with CIN type 2, 40 % will have regression. Higher levels of dysplasia usually progresses to 
cancer in the presence of other cofactors like smoking and impairedimmunity. The 
progression of the disease usually takes 10 to 20 years except in some instances where there 
is rapid progression to carcinomas with aggressive disease. 
CIN is said to be progressed to carcinoma when the malignant cells break through the 
basement membrane of the epithelium and invades the cervical stroma. Further invasion via 
lymphatic or blood route can lead to spread to lymph nodes as well as distant spread. If the 
disease is detected at initial stage by Papinicolaou (Pap) smear test, minimally invasive 
treatment will be sufficient .But if the disease is not detected by screening methods at the 
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early stage, the lesion may progress.If the disease is not detected and treated even in this 
stage then it may spread initially locally to the vaginal fornices, paracervical, parametrial 
tissue or even to neighbouring structures like bladder and rectum. 
PAP SMEAR SCREENING: 
 
Pap smear screening should begin at the age of 21 years every two yearly until the age of 30 
years(9). If three consecutive Pap smear test result comes negative and if there is no history 
of CIN 2, CIN3, DESexposure or HIV infection and if the women is not otherwise 
immunocompromised, screening can be done every three yearly. 
 
Women who had undergone hysterectomy in view of benign reasons who never had history 
of high grade intraepithelial lesion may discontinue testing. Women who have been treated 
for CIN2 and CIN 3 need annual screening at least for 20 years. Those who had hysterectomy 
and had a history of CIN2 or CIN3 should undergo screening with annual pelvic examination. 
 
Fig 3.2: Recommendation for Pap screening 
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4.5 CLINICAL PRESENTATION: 
 
Patient usually presents with complaints of post coital bleeding, inter menstrual bleeding, 
menorrhagia or post menopausal bleeding. In case of chronic bleeding, the patient may 
present with fatigue or other features related to anaemia. In developed countries cervical 
cancer is frequently identified during routine clinical examination. 
 
In case of advance disease conditions, patient may present with feature of renal failure, bowel 
obstruction, foul smelling serosangunious vaginal discharge, pelvic pain, flank or leg pain , 
rectal bleeding, dysuria , hematuria ,or persistent oedema of lower limbs due to lymphatic or 
venous blockage by pelvic sidewall disease. There may be associated pain in the pelvis or 
hypogastrium due to tumour necrosis or pelvic inflammatory disease.If patient is presenting 
with pain in the lumbosacral area, involvement of Para aortic nodes or hydronephrosis should 
be considered. 
4.6 DIAGNOSTIC WORKUP: 
 
When a patient`s Pap smear shows Abnormal Squamous cells of Undetermined Significance 
(ASCUS) and if the HPV status is negative, follow up in one year time period is 
recommended(10). If the second Pap smear also shows positive report, irrespective of the 
HPV status a colposcopy is recommended. If both ASCUS and HPV results are present 
(11)or adenocarcinoma in situ or squamous cell intraepithelial lesion is identified, direct 
biopsies at the time of colposcopy are advised. Endocervical curettage is recommended 
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except in pregnant women. If the biopsy results are negative, same procedure should be 
repeated after 6 months. If they are positive, conisation should be performed. 
 
 
Fig 3.3: Flowchart showing how to proceed with a Pap smear 
Patient who presents with a clinically significant cervical lesion should be evaluated by 
radiation oncologist as well as a gynaecologic oncologist .After getting a careful history, a 
thorough general examination, systemic examination and pelvic examination should be 
carried out. Pelvic examination should include inspection of external genitalia, per speculum 
examination of vagina, cervix, a rectal examination and bimanual palpation of the 
pelvis.Pelvic examination under anaesthesia is useful and is accepted universally forpain free 
clinical staging of the disease and assessment of parametrial involvement or pelvic side wall 
tumour extension. 
MRI can be done if it available to estimate the tumour extension beyond the uterine 
cervix(12). If it is not available then MRI can be replaced by examination under anaesthesia. 
Cystoscopy or rectosigmoidoscopy should be performed in all the patients who are having 
25 
 
symptoms suggestive of vesicovaginal fistula or rectovaginal fistula .It should be also 
performed in patients having stage IIB,III,IV A disease who cannot afford an MRI scan or in  
a  patient  whose MRI shows  features suggestive of bladder or bowel involvement(13). 
 
DIAGNOSTIC WORKUP FOR CARCINOMA CERVIX 
General 
History 
General Examination : Performance status 
                                     Pallor ,icterus ,lymphadenopathy. 
Local Examination:      Inspection of external genitalia 
                                      Per Speculum Examination 
                                      Per Vaginal Examination 
Systemic Examination 
Diagnostic Procedures 
Cytological smear 
Colposcopy 
Conisation(Subclinical tumour) 
Punch biopsies 
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Dilatation and curettage 
Cystoscopy, rectosigmoidoscopy(14) 
Radiographic studies 
 
Chest Radiograph 
 
Ultrasound of the abdomen and pelvis. 
 
MRI/CT Scan(If indicated) 
Laboratory Studies 
Routine blood counts, Blood chemistry, Urine analysis , Blood borne virus 
screening 
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4.7 TNM STAGING 
Primary Tumour (T) 
TNM 
Categories 
FIGO 
Stages 
  
TX   Cannot  assess primary tumour 
T0   No evidence of primary tumour 
Tis* * Carcinoma in situ (preinvasive carcinoma) 
T1 I 
Carcinoma confined to uterus (extension to corpus should be 
disregarded) 
T1a
[†]
 IA 
Invasive carcinoma diagnosed only by microscopy. Stromal 
invasion with a maximum depth of 5.0 mm measured from the 
base of the epithelium and a horizontal spread of 7.0 mm or 
less. Vascular space involvement, venous or lymphatic, does 
not affect classification. 
T1a1 IA1 
Measured stromal invasion 3.0 mm or less in depth and 7.0 mm 
or less in horizontal spread 
T1a2 IA2 
Measured stromal invasion more than 3.0 mm and not more 
than 5.0 mm with a horizontal spread 7.0 mm or less 
T1b IB 
Clinically visible lesion confined to the cervix or microscopic 
lesion greater than T1a/IA2 
T1b1 IB1 Clinically visible lesion 4.0 cm or less in greatest dimension 
T1b2 IB2 Clinically visible lesion more than 4.0 cm in greatest 
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Primary Tumour (T) 
TNM 
Categories 
FIGO 
Stages 
  
dimension 
T2 II 
Cervical carcinoma invades beyond uterus but not to pelvic 
wall or to lower third of vagina 
T2a IIA Tumour without parametrial invasion 
T2a1 IIA1 Clinically visible lesion 4.0 cm or less in greatest dimension 
T2a2 IIA2 
Clinically visible lesion more than 4.0 cm in greatest 
dimension 
T2b IIB Tumour with parametrial invasion 
T3 III 
Tumour extends to pelvic wall and/or involves lower third of 
vagina, and/or causes hydronephrosis or non-functioning 
kidney 
T3a IIIA 
Tumour involves lower third of vagina, no extension to pelvic 
wall 
T3b IIIB 
Tumour extends to pelvic wall and/or causes hydronephrosis or 
non-functioning kidney 
T4 IVA 
Tumour invades mucosa of bladder or rectum, and/or extends 
beyond, true pelvis (bullous oedema is not sufficient to classify 
a tumour as T4) 
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Regional Lymph Nodes (N) 
TNM 
Categories 
FIGO 
Stages 
  
NX   Regional lymph nodes cannot be assessed 
N0   No regional lymph node metastasis 
N1 IIIB Regional lymph node metastasis 
   
Distant Metastasis (M) 
TNM 
Categories 
FIGO 
Stages 
  
M0   No distant metastasis 
M1 IVB 
Distant metastasis (including peritoneal spread, involvement of 
supraclavicular, mediastinal, or paraaortic lymph nodes, lung, live, or 
bone) 
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Fig 4.1: T staging in carcinoma cervix 
 
4.8 PATHOLOGICAL CLASSIFICATION.  
 
Histopathologically , more than 90% of the tumours are squamous cell carcinoma, 7% -10% 
adenocarcinoma and 1-2% clear cell mesonephric type(15). Squamous cell carcinomas are 
sub divided into large cell keratinizing, none keratinizing and small cell carcinomas. 
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According to the degree of differentiation they are subdivided into well, moderately and 
poorly differentiated. 
 
  Fig. 4.2: Histopathology of squamous cell carcinoma cervix 
 
Adeno carcinoma arises from the cylindrical mucosa of the endocervix or the mucin secreting 
endocervical glands.Mucinous is the most common subtype .This type may form mucosal 
gland lined by high columnar cells. In another type the cells resembles those of intestine. The 
epithelium tends to be pseudo stratified and may contain goblet cells. The third variant is 
signet-ring cell adenocarcinoma. 
 
 
In an analysis of 25 patients by Van Nagell et al., it was noted that 5 year survival rate for all 
stages of small cell carcinoma was 54%(16) compared with 68% for large cell non 
keratinizing squamous cell and 74% for keratinizing Squamous cell carcinomas. 
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4.9 PROGNOSTIC AND PREDICTIVE FACTORS: 
 
Prognostic and predictive factors can be classified into 
 
1.Patient related Factors. 
2.General Medical Factors. 
3. Tumour Factors. 
4. Margin status after Radical Hysterectomy. 
5. Histological Grade. 
6. Treatment Duration. 
7. Biomarkers. 
1. PATIENT RELATED FACTORS: 
 
AGE 
 
Age is not a prognostic indicator in carcinoma cervix according to some reports while some 
other authors noted decrease survival in women with age < 35-40 years who has a greater 
frequency of poorly differentiated tumours. Two European studies showed improved survival 
in younger age in contrast to the other studies. Mitchell et al. evaluated 398 women with 
carcinoma cervix Stage I-III treated with radiotherapy. In this study, patients were divided 
into twogroups,non elderly from35 to69 years of age and elderly patients with age >70 years 
of age (n=60).In case of elderly women, co morbidities resulted in diminished ability to do 
intracavitary brachytherapy. Even if the 5 years cause-specific survival and disease-free 
33 
 
survival and were comparable between the two groups, tumour recurrence  rate and death 
from malignancy were more common in elderly group(17). 
 
RACE AND SOCIOECONOMIC STATUS: 
It was noted by several authors that there is a relationship between racial or socioeconomic 
outcome of the patient and treatment outcome. Mundt et al examined in 316 African 
American (18)and 94 white patients undergoing RT for carcinoma cervix the factors affecting 
the outcome. African Americans had a poorer 8 year cause specific survival rates in 
comparison to the white patients. 
 
 Factors resulting in poorer outcomes like low blood Hb was observed in African American 
group. It was demonstrated in Multivariate analysis that race is not an independent prognostic 
factor in carcinoma. In another study, 471 patients diagnosed to have squamouscell 
cervixcarcinoma treated in United States and 215 randomly selected cases from 17 
institutions withmore than 40 % of the minority patients were selected. It was observed that 
African Americans have a poorer initial performance status, higher stage or bulky central 
tumour and a lower pre treatment blood Haemoglobin level. 
 
GENERAL MEDICAL FACTORS: 
 
ANEMIA AND TUMOUR HYPOXIA 
Even if the stage, tumour volume, histopathological type of the lesion and vascular and 
lymphatic invasion are the major prognostic factorin case of a patient with carcinoma 
cervix,blood Haemoglobin level also contributes to the treatment outcome.Pre treatment 
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blood Haemoglobin level has a great impact on radiosensitivity and hence on the treatment 
prognosis. It is desirable to maintain blood haemoglobin level between 12-12.5 g/dL(19). 
 
Whether surgery or radiation therapy is the primary modality of treatment, hypoxic tumour 
cells are more likely to recur loco regionally than well oxygenated tumour cells. It was 
reported by various investigators that there is worse outcomes for patients whose pre 
treatment tumour tissue oxygen measurement was <10 mm Hg(20). 
Usage of recombinant erythropoietin is not an alternative to blood transfusion in order to 
sustain or raise blood haemoglobin levels. This is not encouraged because it results in 
thrombotic complications and there is no proven survival benefit. 
 
OTHER MEDICAL FACTORS: 
 
It was observed in various studies that there is high incidence of pelvic recurrences in patient 
with arterial hypertension, diastolic pressure of >110 mm Hg. Patients who were found to 
have carcinoma of cervix associated with HIV infection had more advanced tumours.They h 
higher rdes of tumour recurrence after treatment and death as a consequence of malignant 
process. 
TUMOUR FACTORS 
HPV SUBTYPE: 
 
HPV 16 and 18strains are the commonest HPV subtype worldwide. Studies have shown that 
the incidence of lymph node metastases and distantmetastases is higher with HPV 18 subtype 
when compared to subtype 16(21). 
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TUMOR VOLUME: 
 
It has been found that there is a close relationship between the size of the tumour, depth of 
stromal invasion and the incidence of parametrial and pelvic node metastases and survival. 
 
In a study on women who underwent hysterectomy, 181 patients with Stage 1B1 (<4 cm)   
had 90% 5 year disease free survival when compared to 48 patients with stage 1B2 disease  
who had 72.8% disease free survival. Various studies have shown that bulky barrel shaped 
lesions results in greater incidence of lymphatic metastases, distant metastases, and pelvic 
recurrence and decreased survival rates. 
Perez et al studied on 1,499 carcinoma cervixpatients, stage IA to IV A.All of them were 
treated with external beam radiation therapy followed by two intra cavitary insertions to 
deliver 70 to 90 Gy to point A. He found out that there is a close relationship between the 
tumour size and pelvic tumour control, distant metastases and disease free survival in all 
stages. 
 
 
MARGIN STATUS AFTER HYSTERECTOMY: 
Positive margin after hysterectomy is one of the high risk factors for local recurrence and 
distant metastases in carcinoma cervix. It is an indication for combined modality 
management with concurrent chemotherapy and radiation therapy. But only very small series 
studies have indicated the significance of close margins. 
 
Viswanathan et al did a study among 284  carcinoma cervix patients(22) ,post radical 
hysterectomy .The crude rates for recurrence were 38% ,20% and 11% for patient with 
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positive margins, close(>0 and <1 cm) and negative margins(>1 cm ) respectively. Post 
operative radiation therapy decreases the rate of local recurrence from 50% to 25% for 
positive margins,17% to 0% for close margin and 10 % to 0% for negative margin. The 
predictors for decreased relapse free survival on univariate statisticalanalysis were depth of 
invasion, positive margin, tumour size, lymphovascularinvasion, and margin status. 
 
HISTOLOGIC GRADE 
 
Reports have shown that there is no significant relation between survival or behaviour of the 
tumour with the degree of differentiation of Squamous cell carcinoma or adenocarcinoma of 
cervix .Alfsen et al did analysis with 417 cervical cancer patients with adenocarcinoma 
histology(23) and 88 with other non Squamous cell histology.  
On multivariate analysis, it was found that small cell histology, vascular invasion, corpus 
infiltration and positive lymph nodes were the significant prognostic factors. Even though 
Reagan et al (24)and  Fu et al opined that there was significant value of histopathological 
differentiation in patients treated with radiation, Crissman et al(25) failed to obtain a 
correlation between the histopathological grading and survival. In this era of chemo radiation 
Monk et al showed that there is no significant impact  of histology or grade on survival in 
case of post operative carcinoma cervix patients with other high risk feature. 
 
TREATMENT DURATION 
 
Overall treatment time is an important factor in tumour control in case of carcinoma cervix 
patients who are receiving radiation therapy. Timely integration of external beam radiation 
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therapy and intracavitary radiation therapy is necessary. Studies have proved that when the 
overall time is prolonged for radiation, there are lower pelvic tumour control and survival 
rates. Chatani et al (26)studied 216 patients diagnosed to have stage IIB to III cervical cancer 
who were treated with external beam radiation and HDR brachytherapy .It was aLSO noted 
in multivariate analysis that the overall treatment time is the most significant factor for local 
tumour control ( p=0.0005) . 
 Fyles et al reported that there was approximately 1% loss of tumour control per day of 
prolongation of treatment beyond 30 days in 830 patients diagnosed to have carcinoma cervix 
treated with radiation alone. Lanciano et al analysed 837 patients diagnosed to have 
carcinoma cervix. It was noted that a four year actuarial in field recurrence increased to20% 
from 6% with the increase in treatment timeto 10 weeks from 6 weeks (27).  
Girinsky et al also noted that 10 year recurrence free survival decreases when the total time of 
treatment exceeded 52 days. It was also noted that there was loss of a1.1%  pelvic tumour 
control  with each day loss of radiation(28). 
 
BIOMARKERS 
 
Several studies were conducted to determine the association between various biological 
markers and disease prognosis in carcinoma cervix. But there was no multivariate analysis to 
assess any independent factor. Noordhuis et al did a systematic review of 42 studies with 82 
biological tumour markers.34 biomarkers showed association with survival(29). 
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4.10 MANAGEMENT OF CARCINOMA CERVIX ACCORDING TO STAGE: 
 
4.10.1 CARCINOMA IN SITU: 
 
In case of carcinoma in situ of cervix, the most important factor in the treatment decision is 
the extent of the disease. The other factors like age, fertility, and other medical co morbidities 
also influence the treatment decision. For ectocervical lesions, various options like loop 
electrosurgical excision procedure(LEEP), laser therapy, conisation and cryotherapy are 
available.  
 
For endocervical canal involvement, in patients to preserve fertility and to avoid radiotherapy 
or more extensive surgery, options like laser or cold knife conisation are available. For post 
reproductive age group, Total Abdominal Hysterectomy or vaginal hysterectomy is an 
established modality of treatment particularly when the malignant process extends to the 
inner cone margin. If the patient is medically inoperable, a single intracavitary brachytherapy 
insertion to deliver a dose of 8000cGy to the vaginal surface can be used. 
 
4.10.2 STAGE IA1: 
 
Carcinoma cervix is staged IA1 when there is micro invasive disease which is not greater 
than 3mm depth and not wider than 7mm. Various options like conisation, Total abdominal 
or vaginal hysterectomy or intracavitary radiation alone is available in management . 
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CONIZATION: 
It is the preferred modality of management in patients diagnosed with carcinoma cervix IA1 
who wishes to preserve fertility if there is no evidence of vascular or lymphatic involvement 
and if the margins of the cone arenegative. 
TOTAL ABDOMINAL AND VAGINAL HYSTRECTOMY: 
 
It can be performed in patients with stage 1A1 who has completed their family. If there is no 
vascular or lymphatic emboli the occurrence of lymph node involvement is very low, hence 
lymph node dissection may not be obligatory. In case of young women ovaries can be 
preserved. 
 
INTRACAVITARY RADIATION: 
In 1A1 lesion when there is no lymphovascular invasion the frequency of nodal involvement 
will be very low. As a result external beam radiation therapy may not be required.In these 
cases,intracavitary brachytherapy can be considered. 
4.10.3 STAGE IA2: 
 
Carcinoma cervix is staged IA2 when the tumour extends 3.1 to 5mm beneath the basement 
membrane and when the transverse diameter is < 7mm. In this group radical hysterectomy 
with pelvic node dissection is recommended as the risk of lymph node metastasis is up to 10 
%. However few studies suggest that the rate of lymph node involvement may be much lower 
and they question that conservative therapy may be sufficient in cases of patients who are not 
having residual disease after conisation. Radical hysterectomy should be also considered in 
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caseswhere the extent of tumour invasion in doubtful due to the presence of invasive tumour 
at the margins of the cone. 
RADIATION THERAPY: 
 
 Intracavitary along with external pelvic irradiation or radical intracavitary radiotherapy can 
be an option in patients who are poor candidates for surgery 
In stage IA,non-bulky IB, and early-stage IIA tumours, primary surgical management with 
hysterectomy is indicated in. In these stages primary radiation therapy results in similar 
outcome. 
 
4.10.4 STAGE IB- II A 
The management of stage I B –II A of carcinoma cervix whether to go ahead with definitive 
Irradiation or radical surgery is still controversial .The preference for one procedure over the 
other depends upon the need to preserve fertility , patient`s general condition and preference, 
characteristics of the lesion , and the resources and expertise available in the institution. In 
some young patients surgery is preferred over RT in attempt in preserving ovarian function 
and not attaining post menopausal state early .However studies have shown that in 50- 60% 
cases only ovarian function is retained even after surgery with no radiation therapy. 
In post menopausal women it has been shown that there is survival benefit in radical 
treatment with chemo radiation therapy over surgery. By this approach the complications of 
surgery can be avoided as well. 
Though surgery gives an opportunity to examine abdomen and pelvis thoroughly it has not 
shown any added benefit to improve patient`s overall survival. 
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The contribution of external beam radiation therapy to improve tumour control in larger 
lesion is documented. Hamberger et al (30)showed that out of 151 patients with stage IA or 
stage IB < 1 cm  treated with intracavitary RT alone, there was no failure in 41 patients with 
stage IA disease, only 4 out of 93 patients with stage IB, small volume disease,3 out of 17 
with more extensive stage IB lesion had regional failure. It was concluded that intracavitary 
brachytherapy is inadequate for larger primary tumour, including stage IB1. 
If external beam RT and brachytherapy is delivered without chemotherapy, the usual 5 year 
survival for stage Ibis 86% to 92%and for stage II A it is 75 %.Concurrent chemotherapy 
improves survival significantly in stage IB-IIA. RTOG 90-01, among 272 stage IB- IIA % 
patients, 8 year over all survival was 55 % with radiation therapy alone versus 78% with 
concurrent chemotherapy and radiation therapy. 
In patients diagnosed with carcinoma cervix stage IB to II A, there are few studies which 
compared the results of radical surgery to definitive radiation therapy. There are no studies 
which compared surgery to chemo radiationtherapy. These studies have shown that there is 
equivalent survival and pelvic recurrence rates in both the arms in those with Stage IB to IIA 
carcinoma cervix. 
STAGE IB1: 
 
It can be treated with external beam radiation therapy combined with intracavitary radiation 
together delivering an equivalent dose of 80 Gy to point A or with radical hysterectomy and 
bilateral pelvic lymphadenectomy. 
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STAGE IB2AND IIA 
 
The management options comprise 
1. Radical radiation therapy( external beam RT with intracavitary radiation) 
2. Radical hysterectomy and bilateral lymphadenectomy 
3. Radiation therapy with  chemotherapy 
ADJUVANT THERAPY AFTER RADICAL SURGERY: 
To decide the need for post operative radiation therapy  , based on the post operative 
histopathology report the patients are categorized as high risk, intermediate risk and low risk 
 
HIGH RISK- 
When the post operative HPE reveals lymph node metastasis, positive surgical margin and 
parametrial extension the patients are classified as having high risk features.. In this case 
adjuvant chemo irradiation with external pelvic irradiation and concurrent weekly cisplatin 
chemotherapy is recommended. 
INTERMEDIATE RISK- 
When there is deep invasion of cervical stroma,lymph vascularinvasion,tumour size>4cms 
,the patient is classified as intermediate risk.. In this case, adjuvant radiation therapy alone is 
recommended if at least two of the above are present. 
LOW RISK- 
When none fo the above factors are present in the Post operative HPE,  the patients are 
considered as low risk. In these patients , no further adjuvant treatment is recommended. 
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4.10.5 STAGE IB2 to IV A 
 
Before 1999,<30% of patients treated with radiotherapy for local advanced carcinoma cervix 
were receiving concurrent chemotherapy. In 1999-2000, it was shown by 5 randomised trials 
that there is a survival benefit in patients with carcinoma cervix treated with radiotherapy and 
concurrent cisplatin based chemotherapy. In 1999, The National Cancer Institute issued an 
alert indicating that concurrent chemo radiotherapy should be considered as the standard of 
care for patients with locally advanced carcinoma cervix. 
Patients diagnosed with carcinoma cervix stage II B to IV A are treated with radiation 
therapy including external beam radiation combined with concurrent chemotherapy and 
brachytherapy. The usageof concurrent cytotoxic agents along with radiation therapy 
provides a radio sensitizingeffect. One of the most commonly used cytotoxic agents in 
squamous cell carcinoma cervix is Cisplatin.  
 
4.11 RANDOMIZED TRIALS ON CONCURRENT CHEMOTHERAPY AND 
RADIATION THERAPY 
 
There are results from several cooperative oncology groups which demonstrated that 
concurrent chemotherapy with cisplatin along the radiation therapy prolongs survival in 
women with locally advanced carcinoma cervix and women with stage I to IIA disease who 
was found to have positive node, positive parametrium or positive margin during primary 
surgery. 
DETAILS OF THE TREATMENT PROTOCOLS OF THE FIVE RANDOMIZED TRIALS THAT 
FORMED THE BASIS OF THE NATIONAL CANCER INSTITUTE ANNOUNCEMENT. 
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Fig. 5.1: Trials favouring chemoradiation therapy in carcinoma cervix 
 
4.12 BONE MARROW 
Bone marrow is a supple tissue found in the inside of bones.In human beings the red blood 
cells are formed from the core of bone marrow located in the head of long bones. This blood 
cell production is called hematopoiesis. Bone marrow makes up 4% of the total body mass in 
humans. In an adult of weight 65 kilograms, bone marrow isroughly 2.6 kilograms. The 
hematopoietic constituent of bone marrow produces in the order of 500 billion blood cells per 
day. Bone marrow also produces the lymphocytes that support the body's immune 
system(31). 
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4.12.1 MARROW TYPES 
 
Fig.6.1:A femoral head with an outer cortex of cortical bone, medulla of 
trabecular bone with red bone marrow and yellow bone marrow. 
 
Fig.6.2: Anatomy of bone including the marrow 
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There are mainly two main types of bone marrow , red and yellow marrow.Themedulla 
ossiumrubra  or the red marrow comprisechiefly of hematopoietic tissue, and medulla 
ossiumflava or the yellow marrow mostly consist of fat cells.The Red blood cells, platelets, 
and most white blood cells come up from the red marrow.At birth all the bone marrow is red. 
As the person grows old, moreof the red marrow is transformed to the yellow type. Finally 
only about half of adult bone marrow remains red.  
 
Red marrow is mainly found in the flat bones likepelvis, sternum, ribs, vertebrae, cranium, 
and scapulae.It is as well found in thecancellousmaterial at the epiphyseal ends of long bones 
like the femur and humerus. Yellow marrow is mainly found in the medullary cavityof long 
bones. In situations where there is severe blood loss, yellow marrow is converted back to red 
marrow to boost blood cell production. 
Apart from the hematopoietic stem cells the other major part of the bone marrow is 
constituted by stromal cells. These tissue do not involve directly in the process of 
hematopoiesis.Majority of these tissue is found in the yellow marrow and smaller 
concentration in the red bone marrow. But it play a major role in haematopoiesis indirectly by 
providing an appropriate microenvironment for the parenchymalcells.They release colony 
stimulating factors that has a significant role in hematopoiesis.Thestromal cells comprises of 
fibroblasts, macrophages, adiposities, osteoblasts, osteoclasts, endothelial cells .Among these, 
macrophages is having a significant role in the production of the red blood cells as they 
deliver iron for the production of hemoglobin. 
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4.12.2 FUNTIONS OF BONE MARROW 
Red blood cells deliver oxygen to the tissues. 
Platelets or thrombocytes (derived from megakaryocytes) help thwart bleeding and assist in 
clotting of blood. 
Granulocytes (neutrophils, basophils and eosinophils) and macrophages (jointly known as 
myeloid cells) battle infections from bacteria, fungi, and other parasites. They also get rid of 
dead cells and remodel tissue and bones. 
B-lymphocytes produces antibodies, while T-lymphocytes can directly destroy or isolate 
invading cells.RBC live for just about 170 days and rest have shorter life spans and have to 
be replenished constantly. An average human requires roughly one hundred billion new 
hematopoietic cells each day. This is performed by the Hematopoietic Stem Cells (HSCs). 
Red marrow parenchyma 
 
Fig .6.3: Hematopoietic precursor cells: pro myelocyte in the center, two 
metamyelocytes adjacent to it and band cells from a bone marrow aspirate. 
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Fig.6.4: Cellular constitution of the red bone marrow parenchyma  
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Fig.6.5: Steps of hematopoesis 
 
4.12.3 AVERAGE LIFE SPAN OF BLOOD CELLS 
 
The average life span of RBC s is about 4 months, WBC s is 18  -36 hrs and that of platelet  
is 9-10 days.If we consider WBC s the life span differ with each type.Neutrophil-5.4 days, B 
lymphocytes 3-4days up to 5 weeks, T lymphocytes last for several months. 
Subsequent tothe discovery of X-rays and radium in 1895 and 1898, scientists found out that 
there can be effects like hair loss and skin damage from their rays. Both theseagents were 
tried experimentally in the treatment of superficial skin diseases and for removing unwanted 
hair. X-rays wasquickly found useful by physicians for diagnostic purpose. Radium wasnot 
found to be useful during this time. By 1913, America started mining radium. At that time 
radium was scarce and expensive .It was kept in small tubes and was inserted directly into 
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cancers or body cavities containing cancer. Inoperable cervical cancer was made curable with 
radium. 
Scientist started their studies on stem cells following the repercussion of the bombings in 
Hiroshima and Nagasaki in 1945. Those patients who died after a prolonged period from 
lower dose of radiation had affected hematopoietic system that could not regenerate adequate 
white blood cells for immunity and sufficient platelet for blood clotting.These changes were 
detected by blood tests after receiving a whole-body acute dose as low as 0.25 Gy. Later, 
from various laboratory studiesit was established that mice that were subjected to whole body 
irradiation developed the same type of radiation syndromes. The mice died two weeks after 
radiation from hematopoietic failure weeks after radiation exposure. It was noticed that 
shielding of a bone or the spleen from radiation helped in preventing irradiation syndrome.  
In 1950 s it was demonstrated by scientists that those mice which had received whole body 
irradiation that developed hematopoietic failure could be rescued by injection of suspensions 
of cells from blood forming organs such as bone marrow. 
In 1956, studies from three laboratories established that direct injection of bone marrow cells 
helps in regenerating blood forming system rather than releasing factors. Till date the only 
acknowledged treatment for hematopoietic failure following whole body irradiation is 
transplantation of bone marrow cells or stem cells to renew the blood-forming system. 
 
From all these historical experiences it was clear that radiation therapy as a treatment 
modality is a double edge sword and accurate  technique to deliver it precisely to the target 
without affecting normal structure remains a never ending quest. 
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The same quest paved way to the evolution of radiation therapy delivery techniques in 
carcinoma cervix  from conventional techniques like AP-PA , Cross fire technique , 4 field 
box technique , 3 dimensional conformal radiation therapy towards Intensity Modulated 
radiation therapy. 
In patients with carcinoma cervix pelvic radiation therapy causes significant haematological 
toxicity. This can be attributed to the fact that more than half of the body’s bone marrow is 
located in the lower lumbar spine , sacrum , os cocci and proximal femora which are included 
in the treatment volume of conventional pelvic irradiation therapy for patients with carcinoma 
cervix(32) 
 
 
Fig. 6.6: Distribution of bone marrow in human body 
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Blomlie V et al(33) conducted an imaging based study on 31 women with locally advanced 
carcinoma cervix. 161 MRI examinations were carried out before during and seven weeks 
after radiation therapy. They found significant changes in the irradiated marrow on T1 
weighted images in all 31 patients. A complete fatty bone marrow was observed on T1 
weighted images after 6-8 weeks of starting radiation therapy in 28 (90 %) of the 31 patients. 
 
 
4.13 STUDIES IN CARCINOMA CERVIX PATIENTS WHICH SHOWED THAT 
CONCURRENT CHEMOTHERAPY INCREASES THE HEMATOLOGICAL 
TOXICITY WHEN COMPARED TO RADIATION THERAPY 
 
Keys et al (34)conducted a trial on patients with large stage 1b cervical cancer to determine 
whether weekly infusion of cisplatin during radiation therapy improves progression free 
survival and overall survival. 183 women were randomised into radiotherapy chemotherapy 
arm and 186 were assigned to receive radiotherapy alone, the rates of overall survival (p 
value =0.008) and progression free survival (p value < 0.001) were appreciably higher in 
combined modality group at the end of four years. In combined therapy group they found that 
there were elevated frequencies of transient grade 3 (moderate) and grade 4(severe) adverse 
haematological toxicity (21 % in combined group vs. 2 % in radiotherapy group). 
 
Rose et al in(35) 1999 analysed 526 women with locally advanced cervical cancer. patients 
were randomised into 3 groups , radiotherapy with cisplatin alone ; radiotherapy in 
combination with cisplatin , fluorouracil and hydroxyurea ; radiotherapy with hydroxyurea 
alone .He found that both the groups who received cisplatin had higher rate of progression 
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free survival when compared to the group that received hydroxyurea alone , but  at the same 
time it was analysed that the groups who received cisplatin based combination chemo 
regimen were  having increased frequencies of grade 3 grade 4 haematological toxicity. 
 
From these studies it was observed that Concurrent chemo radiotherapyis leading to increased 
haematological toxicity.  This predisposed the patient to infection,hospitalisation,blood 
transfusion and usage of growth factors. There resulted in delayed or missed chemotherapy 
cycles and even break in treatment.  
This brought the question in mind of many that whether this delay in treatment can 
compromise disease control. It was found that treatment with any cytotoxic agent including 
radiation is triggering clonogens in the tumour to divide faster than before which led to 
accelerated repopulation .Even if the tumour was found to be shrinking and regressing; the 
surviving clonogens were dividing and increasing in a more rapid fashion than ever. Various 
analyses suggest that this clonogenic repopulation in human cancers accelerates at about 28 
days after the initiation of radiation therapy in a fractionated regimen. This ascertainedthat 
treatment should be completed as soon after it has begun as is practical. 
 
In their study on the effect of treatment duration in the local control of carcinoma cervix 
Fyles et al showed a significant effect of treatment duration in 830 patients with carcinoma 
cervix treated with chemo radiation therapy. They found that the loss of control consistently 
declined approximately 1% per day of treatment prolongation beyond 30 days(36). This is 
consistent with the occurrence of accelerated repopulation which alarms at timely completion 
of treatment. 
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Rachelle et al analysed the effect of total treatment time on outcome in 837 patients with 
locally advanced carcinoma cervix. A statistically significant decrease in survival ( p= 
0.0001) and pelvic control ( p=0.0001) was demonstrated with increase in total treatment 
time from less than 6 , 6 to 7.9 , 8 to 9.9 and 10+ weeks .This was significant in patients with 
carcinoma cervix stage III  and above . 
 
Patient should receive ideally 5-6 doses of concurrent weekly cisplatin along with radiation to 
achieve the beneficial radio sensitising effect of chemotherapy. Therefore any modality that 
may help in preventing haematological toxicity which results in delay in delivery of 
chemotherapy will help in increased local control and disease free survival. 
4.14 RADIATION THERAPY IN CARCINOMA CERVIX 
 
 
External beam radiation therapy is routinely administered in patients with carcinoma cervix 
stages IB2 to IV A along with concurrent chemotherapy in a curative fashion. It may be 
administered in stages IA to IB1 if those patients are inoperable or if they prefer avoiding 
surgery. In stage IVB, palliative radiation to pelvis is offered for selected indications such as 
to stop vaginal bleeding, alleviate urethral obstruction from extrinsic compression or to 
relieve pain 
External beam radiation should cover the primary cervical tumour, bilateral parametrium, 
uterosacral, uterine or vaginal extension and most importantly the microscopic disease 
present in the pelvic lymph nodes. The primary drainage lymph nodes from the cervix 
include all the pelvic lymph nodes including the lower common iliac nodes, the external iliac 
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nodes, the presacral nodes and the obturator nodes. These nodes are usually covered using a 
whole pelvic field with the superior border of the field at L4 –L5 junction. 
 
4.14.1 ORGAN AT RISK 
 
The main aim of radiation therapy is to deliver adequate dose to the target volume and to 
avoid dose deliverance to the surrounding normal structures as much as possible. While 
considering radiation to uterine cervix, the main organs at risk include small/large bowel, 
rectum,bladder, and bilateral femoral head. Dose constrains required for an optimal IMRT 
plan have not been standardised .According to RTOG0921(37), the normal tissue constrains 
are given as follows  
 
ORGAN AT RISK DOSE CONSTRAIN 
Small / large bowel( bowel bag) V45< 25% 
Bladder V45 < 35% 
Femoral Head V45< 25% 
Rectum V50 <50% 
 
Table1.1: Constrains of organs at risk 
The application of these OAR constrains is practical only in conformal radiation therapy and 
not in conventional techniques.In RTOG0921 study, bone marrow was not considered as an 
OAR and constrains for the same are not known.  
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4.14.2 TARGET 
The target volume in any radiation therapy plan should include Gross tumour volume (GTV), 
clinical target volume (CTV) and planning target volume ( PTV)(38) . GTV accounts for 
clinical or radiological gross tumour volume. CTV= GTV +potential regions at risk for 
microscopic spread. PTV = CTV + margin for patient and organ movement and daily setup 
reproducibility. 
4.15 DIFFERENT TYPES OF RADIATION THERAPY TECHNIQUES 
 
External beam radiotherapy is delivered using either conventional techniques like four field 
box; AP-PA technique or by conformal techniques like 3D CRT and IMRT. 
4.15.1 FOUR FIELD BOX TECHNIQUE 
 
In four field box technique radiation is delivered using four fields, AP, PA, and 2 lateral 
fields .Patient is first positioned supine .Midline is checked with the help of plain x-
raysimulation. In the AP –PA field the upper extent is set at the L4-L5 interspace in order to 
cover the lower common iliac nodes. The lateral borders are kept 1.5 to 2 cms from the pelvic 
brim in order to cover the iliac nodes. The inferior border is kept below the obturator foramen 
if vagina is not involved or 2 cm below the lower extent of the tumor. When there is vaginal 
involvement the entire length of the organ is treated up to the introitus. For the lateral field, 
the superior and inferior border is kept the same as that of AP-PA field. The posterior border 
is set in such a way that the entire sacrum is included within the field as the uterosacral 
ligaments are at high risk of microscopic extension. The anterior border of the lateral field is  
set at a vertical line anterior to the pubic symphysis or 3 cm anterior to the anterior border of 
forth lumbar vertebrae, in order to cover the external iliac lymph nodes. 
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4.15.2 3 DIMENSIONAL CONVENTIONAL RADIATION THERAPY 
 
The most common acute side effects experienced by carcinoma cervix patients on 
radiotherapy includes nausea , vomiting , diarrhoea , irritation of urinary tract and bone 
marrow suppression . These side effects are worsened when administered along with 
concurrent chemotherapy. Late side effects of pelvic irradiation in carcinoma cervix include 
anatomical and physiological alterations which include strictures, fistula formation, soft 
tissue fibrosis, lymphedema, increased chance of fractures all of which lead to severe 
morbidity. Even if these late side effects are less well documented,with the recent emphasis 
on long term quality of life, experts have recommended that these late toxicities can be 
prevalent. 
In the past two decades the external radiotherapy techniques have evolved dramatically. With 
modern imaging techniques it is easy to differentiate target volume from the normal tissue 
structures in the pelvis. Traditional methods of radiation delivery like four field box 
technique based on bony landmarks delivers unnecessary radiation to normal structures like 
bladder, rectum, small intestine and bone marrow. The widespread usage of cross sectional 
imaging like CT scan and MRI has resulted in use of 3 dimensional treatment planning. 
CT simulation helps in direct assessment of extent of tumour, pelvic vessels and location of 
pelvic nodes. Oral contrast helps to identify the small bowel as well .During treatment 
delivery multi leaf collimator is used in each field to block unnecessary radiation to skin, soft 
tissue,muscle, small bowel and portions of the anus and lower rectum.  
Various studies have shown that better dose delivery to target volume with decreased dose to 
OARs is achievable with 3D CRT technique when compared to conventional four field box 
technique. While planning the superior border is set based on the CT visualised bifurcation of 
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common iliac nodes into external and internal iliac nodes. The inferior border is kept 2 cm 
below the lowermost extent of the tumour. The lateral border of the anterior field is based 
upon the iliac node location as per CT.  
Bonin et al did detailed anatomic mapping of pelvic lymph nodes using lymphangiography in 
22 patients with carcinoma cervix. They concluded that with the margin of 1.5 cm on the 
pelvic brim used in the AP portal of conventional four field box technique and lateral field 
anterior edge as a vertical line anterior to the pubic symphysis, 10 patients (45%) had 
inadequate nodal coverage in the lowest lateral external iliac group(39). The omissions of 
these nodes can be prevented with CT simulation based contouring used in 3D CRT 
technique. 
Zunino et al conducted similar lymphangiographic study to analyse the appropriateness of 
posterior coverage of the target volume in conventional box technique for carcinoma 
cervix(40). After defining the PTV with a 3 D planning system, they compared the field 
configuration of the simulator planning with a second one based on defined PTV. It was 
found that planning by simulation resulted in one geographic miss and the coverage of PTV 
was inadequate in 10 cases. 
Yamazaki et al compared 34 patients with cervical cancer treated with CT simulation based 
planning and 40 patients who received external beam RT with conventional technique. With a 
follow up of 60 months, the 5 year tumour control was 94% with conventional technique and 
100% with CT based technique. The incidence of grade II or III bowel complications was 
significantly lower in conformal technique when compared to conventional technique(41). 
These studies emphasized that 3D CRT is superior to conventional technique in target 
coverage and reduced dose to organs at risk. 
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4.15.3 INTENSITY MODULATED RADIATION THERAPY 
 
IMRT was developed using techniques that are required for inverse planning whereby the  
necessary dose to the target volume and dose constrain to the organs at risk are  prescribed 
and then the programming system works backward to develop the requisite beam intensities. 
In IMRT, the intensity of the beam is spatially modulated using the motion of multi leaf 
collimators. IMRT requires delineation of the target volume and organs at risk .Dose to the 
tumour is prescribed in terms of gross tumour volume (GTV), clinical target volume (CTV) 
and planning target volume(PTV).  
Dose is prescribed after making a best plan based on dose volume histograms. The 
prescription is optimised based on dose volume constrains specified for both target volume 
and organs at risk .More time and resources by physicians and technologist are required for 
IMRT planning and treatment delivery when compared to 3D CRT .The tumour volumes for 
the treatment are delineated with the help of clinical findings, imaging and clear 
understanding about loco regional pathway of spread of the tumourand anatomical barriers of 
tumourextension. 
Organs at risk coming within the irradiated volume such as bowel,bladder, rectum and 
femoral heads must be contoured individually and appropriate dose constrains are prescribed. 
To maximise the therapeutic ratio, an IMRT plan appropriately optimises the dose 
distribution to the target volume and OARs using a computer inverse algorithm and through 
multistep physician feedback after the review of isodose plans and dose- volume histograms 
generated by the computer. Adhering to the dosimetric plans developed the linear accelerator 
sets up specifications by which the target volume receives the ultimate intended dose with the 
integration of multiple segments of radiation exposure using multileaf collimators. 
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Dosimetric studies have shown that IMRT can reduce normal tissue irradiation significantly 
in gynaecologic patients especially bowel, bladder and rectum. 
Roeske et al selected 10 women with  gynaecological malignancies to assess the ability of 
IMRT to lessen the volume of small bowel irradiated in comparison to normal conventional 
planning(42) .A planning  CT scan was obtained for each patient target volume and OARs 
likerectum, bladder and small bowel were delineated for each patient . 2 plans were created, a 
standard four field box plan and an IMRT plan for each patient. Both plans were normalised 
to deliver 45 gray to the PTV , dose- volume histograms and isodose distributions were 
compared .In all the 10 patients IMRT plan reduced the volume of irradiated  small bowel at 
doses above 30 gray . The average volume of irradiated small bowel was reduced by a factor 
of two at the prescription dose (17.4 versus 33.8%, p=0.0005) .In addition at the prescription 
dose the average volume of rectum and bladder irradiated was reduced by 23%. The average 
PTV dose delivered by IMRT and conventional plans were 47.4 Gy and 47.8 Gy respectively. 
It was concluded that IMRT is auseful means of reducing the volume of irradiated small 
bowel in patients with gynaecological malignancies in patients who received whole pelvic 
radiation therapy. 
 In a study was conducted by Mundt et al , 40 patients with gynaecological malignancy were 
selected after making customised immobilisation(43). All patients were evaluated with 
contrast enhanced CT and target volume was contoured. Using available software, 7 or 9 
fields, 6 MV, coplanar IMRT plans were drawn up for all the patients. The acute 
gastrointestinal and genitourinary toxicity during treatment was scored on a 4 point scale :0, 
none; 1, mild , no medication required ;2, moderate , medication required ;3 , severe, 
treatment break or cessation, hospitalisation.  
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The results were analysed and it was found that IMRT plans are providing excellent PTV 
coverage with substantial sparing of adjacent normal structures. On an average 98.1% of the 
PTV received the prescription dose. The proportion of PTV receiving 110% and 115% of the 
prescribed dose were 9.8 % and 0.2 % respectively. IMRT was well tolerated by all the 
patients, no patients developed grade 3 gastrointestinal toxicity. When compared to 
conventional group grade 2 acute gastrointestinal toxicity was less common in IMRT group 
(60 versus 91 %, p=0.002). Grade 2 genitourinary toxicity was seen less in the IMRT group. 
Selvaraj et al studied 10 patients with gynaecological malignancy at the University of 
Pittsburgh. The aim of the study was to evaluate the feasibility of IMRT plan in these patients 
and to determine the acute and long term toxicity with IMRT plan when compared to 3D 
CRT plan. A seven field technique using 6MV photon was used for IMRT. Restrains on 
small bowel for IMRT was set as 23.0 Gy +/- 5% and 35.0Gy +/- 5% for the rectum and 37.5 
Gy +/- 5% for bladder while delivering 45 Gy to the target volume in 1.8 Gy per daily 
fraction. The volume of small bowel receiving doses more than 30 Gy was reduced by 52 % 
in IMRT plans when compared to 3DCRT. Similarly in rectum, there was reduction of 66% 
and bladder 36% without compromising dose to the target volume.  
A similar study was conducted by Portelance et al (44)to prove that intensity modulated 
radiotherapy reduces small bowel , rectal , and bladder doses in patient with cervical cancer 
receiving pelvic radiotherapy. It was concluded that with comparable target coverage, normal 
tissue sparing was superior with IMRT in the treatment of cervical cancer when compared to 
other techniques 
While the above studies were conducted in order to show the superiority of IMRT over other 
conventional or 3D techniques in the management of gynaecological malignancies in 
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reducing bowel and bladder toxicities, it was also noted that there was an additional benefit of 
reduced incidence and severity of acute haematological toxicity.  
This benefit in haematological toxicity was seen without considering bone marrow as 
constrain in the treatment planning. The reduction in volume of bone marrow irradiated 
especially the iliac crest was a natural result of IMRT planning. 
These observations paved the way to the concept that contouring bone marrow as a separate 
organ at risk and giving a constrain for the same in IMRT treatment planningmay help in 
better sparing of bone marrow which can result in decreasing haematological toxicity without 
compromising the coverage to the target.  
Mundt et al reported the first clinical series of 40 patients treated with whole pelvic IMRT in 
2001, most of whom were post hysterectomy patients. They compared the results of this 
study with 35 historic controls treated with conventional fields. They focussed on reduction 
of the volume of OARs irradiated to decrease toxicity. He noticed that IMRT patients showed 
a decrease in hematopoietictoxicity. There was significant drop in the volume of bone 
marrow receiving more than 30% of the treatment dose. On  average the IMRT planning 
resulted in a 50% reduction in the bone marrow volume irradiated to doses more than 22.5Gy 
m. Acute hematologic toxicity in patients treated concurrently with chemotherapy was 
significantly less when treated with IMRT( 40% versus 12.5%, p=0.06), attributed to less 
iliac  crest bone marrow volume being irradiated(45) . 
Lujan AE et al selected 10 patients with cervical or endometrial cancer formerly treated with 
IMRT for analysis. 3 plans were formed for each patient: a standard 4 field plan, IMRT 
treatment plan excluding bone marrow and a bonemarrow sparing IMRT (BMS IMRT) plan 
in which bone marrow is included as an additional treatment planning constrain(46)I. For 
63 
 
each of the 10 patients, BMS-IMRT treatment plans confirmed a significant reduction of the 
volume of bone marrow which received more than 40% (18 Gy) of the prescription dose ‘(45 
Gy) in comparison with both IMRT and 4 fields box treatment technique. BMS IMRT 
resulted in just 60% of the bone marrow volume irradiated to > 50% of the dose compare 
with 87.4% ( p<0.001) of the bone marrow volume in a four field plan and 75.7% (p<0.003) 
of the volume in an IMRT plan . The BMS IMRT plan resulted in considerable sparing of all 
other normal tissue that was comparable to the IMRT   plan. In all 10 cases, the BMS IMRT 
plan did not produce any significant differences in the PTV and small bowel dose volume 
histograms, compared with the IMRT treatment plan. 
Brixey et al conducted a study to assess the impact of intensity modulated pelvic radiation 
therapy on acute haematological toxicity in gynaecological patients. 36 patients diagnosed to 
have gynaecological malignancy who received IMRT between February 2000 and June 2001 
was recruited in the study, target volume consisted of uterus,parametrium,and uppervagina, 
presacral and pelvic lymph nodes. Using 7 or 9 coplanar beams IMRT plans were generated, 
their aim was to acquire adequate coverage to the target while minimising the dose to 
bladder, rectum and small bowel. Bone marrow was not used as a constrain in the planning 
method. The variable used to analyse acute haematological toxicities included white blood 
count, absolute neutrophil count, platelet count and haemoglobin. These variables were 
analysed before RT and weekly during RT. As a comparison, 88 patients treated to attain the 
same target volume and same total dose (45 Gy) with conventional four field radiation was 
analysed. It was found that there was no differences in the baseline white blood cell count, 
absolute neutrophil count, platelet or haemoglobin levels between the two groups. It was 
observed that significant haematological toxicity was uncommon in women treated with RT 
alone and it was similar in both the groups. However, patients who received whole pelvic 
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radiation therapy with concurrent chemotherapy experienced more grade 2 or greater white 
blood cell toxicity (60% versus 31.2 %, p=0.08) and absolute neutrophil count (1874 
versus2669, p=0.04) nadirs than intensity modulated whole pelvic radiotherapy. It was also 
found that chemotherapy was withheld more often in conventional RT group due to acute 
haematological toxicity (40% versus 12.5%, p=0.06). Therefore, it was concluded that IMRT 
is having a favourable impact on acute haematological toxicity in gynaecological patients 
especially in those who are receiving concurrent chemotherapy(47). 
Loren et al did a comparative study between bone marrow sparing IMRT with  four field box  
technique and AP-PA technique in 7 patients with carcinoma cervix(48). Uterus, cervix, 
upper vagina,and parametrium, presacral and other pelvic lymph nodes were included in 
CTV.Bladder, bowel, rectum and pelvic bone marrow were considered as normal tissues 
which are organs at risk.Comparison was made between the DVH curves for the planning 
target volume and normal tissues in BoneMarrow Sparing - IMRT versusother conventional 
techniques. It was found that Bone Marrow Sparing IMRT is superior over conventional 
techniques in reducing the total dose received by the bonemarrow,bladder, small bowel and 
rectum. BMS IMRT reduced bone marrow dose to less than 16.4 Gy . It was concluded that 
Bone Marrow Sparing IMRT can reduce irradiation of pelvic bone marrow when compared 
to either conventional techniques. 
In view of  various study results it was concluded that with an IMRT plan in which bone 
marrow is contoured as an OAR , adequate dose coverage to the target with reduced dose to 
other normal structures including bone marrow is achievable . However the clinical 
importance and best possible technique of bone marrow sparing IMRT in patients with 
gynaecological is still under evalaution. 
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Various bone marrow sparing studies have mainly focussed on iliac crest bone marrow 
sparing .However information from various imaging,histopathologic and clinical studies have 
pointed out that regions of pelvic bone which are exposed to radiation such as lumbosacral 
spine, ischium, pubis and proximal femur are also major contributing factor in 
haematological toxicity.  
Differentstudies were performed to determine factors predictive for haematological toxicity 
in patients receiving concurrent chemo radiation.  
Kevin et al did retrospective study on 40 women who received concurrent chemo radiation 
for cervical cancer(49). A common terminology criterion for adverse events (version 3.0) 
wasconsidered to define haematological toxicity. Various predicting factors for 
haematological toxicity such as age ,BMI, transfusions and volume of irradiated bone marrow 
were incorporated in the data scrutiny .Out of the  40 patients, 13 patients had grade 0 or 
grade1Haematological Toxicity,27 patients had grade 2 to 4 Haematological toxicity. 
Multiple logistic regression analysis  was done which showed that volume of bone marrow 
receiving 20 Gy (V20) for whole pelvic bone showed significance towards grade 2to grade 4 
haematologicaltoxicity. A partitioning analysis to predict grade 2 and more Haematological 
toxicity showed value of around 80% for V20 of whole pelvic bone implying that  if the 
volume of bone marrow receiving 20 Gy exceeds above 80%, the risk of developing grade 2 
and more haematological toxicityexceeds by a factor of 4.5. 
Mundt et al analysed 37 cervical patients receiving chemo radiation  , for each patient bone 
marrow contoured , was divided into 3 sub sites ; lumbosacral spine , ilium and lower pelvis . 
The volume of each region receiving 10,20,30,>/= 40 Gy was calculated. It was found that 
increased pelvic bone marrow V10 was associated with increased grade 2 leukopenia and 
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neutropenia. It was found that there was no association between haematological toxicity and 
V30 and V40. It was concluded from his study that volume of pelvic bone marrow receiving 
low dose radiation is the predictor for haematological toxicity(48).   
In order to put the hypothesis to the test that increased pelvic bone marrow irradiation can 
lead to increased haematological toxicity in patients receiving chemoRT and to develop a 
normal tissue complication chance for haematological toxicity, Rose et al conducted a study 
on 44 cervical patients. The volume of bone marrow receiving more than 10 and 20 Gy and 
its association with hematologic nadirs were tested using linear regression model. It was 
observed that there was significant negative correlation between WBC nadir and V10 
(regression coefficient = -o.06, p=0.009) and V20 (regression coefficient = -0.044, p=0.010). 
Patients with V10 > 95% were highly likely to experience more than or equal to grade 3 
leukopenia than were patients with V20 > 76(50). It was concluded that as the irradiated 
pelvic bone marrow volume increases, haematological toxicity increases. Efforts to restrict 
V10 < 95% and V20 < 76% may reduce haematological toxicity. 
At present as there are no standard guidelines for contouring bone marrow, various methods 
are practiced. Among them Whole bone contouring and freehand contouring of inner cavity 
of bone are the commonly used techniques. 
Loren et al, in their study to analyse dosimetric predictors of acute haematological toxicity in 
carcinoma cervix patients treated with concurrent chemoRT contoured bone marrow by 
delineating the external outline of the bone from L4-L5 junction to the inferior border of 
ischial tuberosities. 
PET CT technique  is the optimal technique in delineating bone marrow as it helps in 
delineating the active bone marrowbased upon the SUV value’s based technique is asurrogate 
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for the volume of bone marrow and is considered as arepresentative of the actual marrow 
delineated using PET CT.Two contouring methods are available for bone marrow contouring 
on CT scans, free hand contouring and auto contouring.Free hand bone marrow contouring,is 
considered better than auto contouring in order to create an acceptable bone marrow volume 
for radiation planning. 
In free hand contouring, two methods are used to contour marrow worldwide, either 
contouring the entire bone marrow outside the cortex which will represent the bone marrow 
or just contouring the inner hypodense area in the bone adjusting the bone window in CT 
scan which will also represent the marrow. 
Various pilot studies are have compared these two methods to see which is more accurate in 
contouring the bone marrow. Nomulti institutional studies has been done so far on the same 
and there is no universally accepted guidelines for bone marrow contouring. 
Recent advances in the radiation therapy delivery in the management of carcinoma cervix 
include tomotherapy and proton therapy. Tomotherapy is a combination of IMRT with the 
precision of inbuilt CT technology in the same .Using tomotherapy we can deliver the 
radiation even more precisely to the tumor than IMRT technique. With the help of inbuilt CT 
scan, it is possible to confirm the position of the tumor each day during treatment with which 
the advantage of adaptiveradiation. All these helps in increasing dose conformity to the tumor  
there by decreasing the dose to the normal structures like bowel , bladder and bone 
marrow(51).Recent studies on proton therapy and carbon ion therapy in carcinoma 
cervixhave shown that the tumor control , morbidity and survival are similar to that seen in 
conventional techniques (52). 
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5.METHODS AND MATERIALS 
 
Data set from 16 women with Carcinoma cervix treated in our institution from July 2013 to    
January 2014 using 3D CRT or IMRT were selected for the study.  
5.1 INCLUSION CRITERIA: 
CT scans of  
1. Female patients of more than 18  years of age  
2. ECOG 0-1 
3. With squamous cell carcinoma cervix 
4. Diagnosed to have carcinoma cervix IIA to IVA ( FIGO staging) 
5. Patients who were planned and treated with radical chemo irradiation with or without 
brachytherapy and , treated with conformal techniques.dile 
6. Patients who already had CT scan in our institution. 
 
5.2 EXCLUSION CRITERIA 
 
1. Female patients less than 18 years of age  
2. ECOG >1  
3. Patient diagnosed to have Carcinoma cervix with histology other than squamous cell. 
4. Patients with FIGO stage IA, IB and IVB 
5. Patients who did not receive radical chemo irradiation 
6. Patients who were treated with conventional technique , and did not have CT scan in 
our institution 
69 
 
All the 16 patients who were selected in the study had CT scan with 5mm slice thickness 
from the diaphragm to midthigh. These images were imported to Eclipse Treatment Planning 
version 10.0.39. Following this, after discussing with radiologist and with clinical correlation 
Gross Tumour Volume was drawn. The Gross Tumour Volume (GTV) was defined as the 
gross disease determined from clinical information and imaging .CTV or the clinical target 
volume was the area considered to have potential microscopic spread. This was contoured 
separately as primary CTV and nodal CTV.Primary CTV included the entire 
GTV,uterus,cervix, parametrium,bilateral adnexa including ovaries and upper half of the 
vagina if there was  minimal or no vaginal involvement ,upper two third of the vagina if 
upper vagina was involved and entire vagina if there was extensive vaginal 
involvement.Nodal CTV included all the regional lymph nodes like the internal (hypo gastric 
and obturator), external, and common iliac lymph nodes and pre sacral nodes. For contouring 
the nodal CTV, initially the vessels were contoured and a 7 mm margin to this 
vesselproduced the nodal CTV.Psoas muscle, piriformis, bone,and intraperitoneal small 
bowel were excluded from the CTV.About 1-2 cm of tissueanterior to the S1, S2 and S3 
sacral segments was added to the CTV in order to include the presacral lymph nodes and 
uterosacral ligaments.Antero-lateral external iliac lymph nodes that lie just before the 
inguinal canal were excluded from the CTV .Nodal CTV was stopped at the level of the 
femoralhead. The CTV of the nodes were also stopped 7 mm from L4/L5 junction to account 
for the PTV.The final CTV was created fusing the primary CTV and the nodal CTV.A 
margin of 7mm all around the final CTV was used to generate the PTV.PTV or the planning 
target volume was given to account for the daily set up error and organ motion and was 
limited at L4/L5 junction. 
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FIGURE SHOWING DELINEATED GTV, CTV AND PTV ON CT SCAN: 
 
 
-PTV              - CTV             - GTV            -BODY 
Fig 7.1: Delineation of GTV, CTV and PTV  
The normal Organs at risk contoured included the bladder,small bowel,rectum, femoral heads 
and bone marrow. 
Bladder was outlined on all slices,together with the portion lower to the planning target 
volume.Rectum was contoured on all slices, including the portion inferior to the planning 
targetvolume.Superiorly rectum was contoured till it leaves the posterior pelvis around the 
region of therecto sigmoid.Bowel bag was contoured at least 2 cm above the planning 
targetvolume.The femur was contoured including the femoral head , the neck and upto the 
lesser trochanter or upto the level of last cut of ischial tuberosity. 
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FIGURE SHOWING DILENIATED ORGANS AT RISK IN CARCINOMA CERVIX IMRT PLANNING 
CT: 
 
 
 
            -           
BODY                      -BOWEL 
 
  Fig.7.2: Delineation of bowel bag on CT scan 
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        -BLADDER            - RECTUM               -BODY 
 
 Fig.7.3: Delineation of bladder and rectum 
 
 
           -FEMORAL HEAD                      - BODY 
Fig 7.4: Delineation of femoral head 
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In bone marrow sparing IMRT plans alone (BMS-IMRT), bone marrow was drawn as a 
separate organ at risk.Bone marrow was contoured using free hand technique in each CT cut 
including entire L5 vertebral body, sacrum,coccyx, ileum,ischium, pubis and femoral head 
extending down till the last cut of ischial tuberosity on the CT.2 cm 3D brush was the tool 
used in contouring the bone marrow in all the patients. 
5.3 DELINEATION OF BONE MARROW 
 
FIGURE SHOWING BONE MARROW DILENIATED ON CT SCAN: 
 
 
  -   BONE MARROW              -BODY 
Fig.7.5: Delineation of bone marrow on CT scan 
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Constraints to the organs at risk and the target volume were prescribed as per the standard 
RTOG guidelines given below. 
 
PTV (Planning Target Volume):  
Prescription Dose: 5040 cGy in 28 fractions. 
Desirable D 98 = 50.4Gy, Acceptable D98= 47.88Gy ,D 2cc < 55.44Gy 
47.88Gy D 98- Dose received by 98 % of the target volume. 
 
CONSTRAINTS TO ORGANS AT RISK( RTOG-0921) 
 
Small Bowel – V 45 < 25%  
V 45- Volume of the OAR receiving 45 Gy. 
 
Femoral Head- V 45 < 25% 
V 35< 15% 
Bowel -    V 45 < 25% 
Bladder-             V 45 < 35% 
Rectum -              V 50 < 50%. 
 
5.4 CONSTRAIN TO BONE MARROW: 
 
Currently there is no universally accepted bone marrow constrain for treatment planning 
.Rose et al, proposed V 10 <95%andV 20 < 76%(V 10 and V 20  represented the volume of 
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bone marrow getting 10 Gy and 20 Gy respectively) as  bone marrow constrain after 
correlating with grade 3 bone marrow toxicity(53). 
 
Following this four treatment plans were developed for all of the patients. 
 
1. Conventional Four field box plan. 
2. ThreeDimensional Conformal Radiation Therapy (3DCRT) 
3. Intensity modulated radiation therapy (IMRT) 
4.Bone Marrow Sparing Intensity Modulated Radiation Therapy (BMS- IMRT). 
 
CONVENTIONAL FOUR FIELD BOX PLANNING 
 
Four field box technique was modelled same as conventional 4 field planning except the fact 
that instead of putting shields manually, multi leaf collimators were used for shielding the 
upper corners in anteroposterior and posterior upper corner in lateral fields  .In this technique 
Organs at risk were not subjected to any shielding. Planning was done using 2 anteroposterior 
and 2 lateral 6 MV  beams with equal weightage . 
 
3 DIMENSIONAL CONFORMAL RADIATION THERAPY (3DCRT) 
 
In three dimensional conformal radiation therapy (3DCRT) planning, beams were added in 
different gantry angles or sometimes with same gantry angle according to the tumour shape 
and coverage.The main difference from 4 FIELD BOX shaping in this planning was, along 
with shaping of target with multi leaf collimators the organs at risk were also 
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shielded.3DCRT planningconsidered as forward planning was modelled such that it provided 
an optimal coverage of PTV and  respected  the dose constraints of the organs at risk in the 
best possible way. 
INTENSITY MODULATED RADIATION THRAPY (IMRT) 
 
Intensity modulated radiation therapy planning is otherwise named as inverse planning. In 
this first the dose to the tumour along with the tolerance dose constraints to the organs at risk 
were initially fed in the planning system. The organs at risk considered in the plan included 
bowel, bladder, rectum and femoral head. Using AAA planning algorithm, plans were created 
with 7 to 9 non coplanar beams using, 6MV energyto get adequate tumour coverage and dose 
to the organs at risk within the tolerance limits as per the guidelines. 
 
 
BONE MARROW SPARING INTENSITY MODULATED RADIATION THERAPY   
(BMS- IMRT). 
 
 Bone marrow sparing IMRT plans were also similar to IMRT plans. The addition 
in this plan above IMRT plan was, bone marrow was contoured as an extra organ at risk with 
dose constrain. This dose constrain was also incorporated with other OAR s dose constrain to 
the planning system and the plans were modelled. 
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6.DATA COLLECTION: 
 
Once all four plans were modelled ,plan evaluation was done.Dose volume histogram (DVH 
curves), isodose curves, dose colour wash and presence of hot spot were used for plan 
evaluation. It was analysed that whether the values are fulfilling the requirement as per 
RTOG guidelines. As the objective of the study, theparameters looked into were 
1. Volume of bone marrow receiving 10 Gy (V 10) and Volume of bone marrow 
receiving 20 Gy (V 20) in various plans. 
 
2. Whether there is adequate dose coverage to PTV with bone marrow sparing IMRT 
plan in comparison to other planning techniques? 
 
 
3. Whether the doses to the organs at risk are within the acceptable limits of RTOG 
guidelines with BMS- IMRT plan? 
 
The end point of the study was to assess whether it is feasible to create an IMRT plan 
in which bone marrow is contoured as an organ at risk with a given dose constrain and 
to see whether it is possible to decrease the dose to bone marrow when compared to 
other plans in which bone marrow is not considered as an organ at risk without 
compromising the dose to the target volume and increasing dose to other organs at 
risk. 
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Volume of bone marrow receiving 10 Gy (V 10) and Volume of bone marrow receiving 
20 Gy (V 20) in various plans. 
This data was analyzed from the Dose Volume histograms of bone marrow in all the four 
plans for all 15 patients. For each patient, for all four plans from the DVH curves, the volume 
of bone marrow receiving 10 Gy and 20 Gy was documented. 
 
Whether there is adequate tumour coverage with Bone marrow sparing IMRT plan in 
comparison to other planning techniques? 
The assessment of adequate tumour coverage was made by observing the dose received by 
98% of the planning target volume ( D98)  and the maximum dose received by 2cc volume of 
the PTV ( D 2cc).The data was collected for all the four plans for all patients. 
 
Whether the doses to the organs at risk are within the acceptable limits of RTOG 
guidelines with BMS- IMRT plan in comparison with other techniques? 
The organs at risk considered in all the four plans were femoral head, bowel, bladder , rectum 
and bone marrow .As per the RTOG guidelines normal OAR s dose constraints, for femoral 
head volume receiving 35 Gy and 45 Gy (V 35 and V 45)was measured from the dose 
volume Histograms (DVH). For bowel, the volume receiving 45 Gy was measured (V45).For 
bladder and rectum, the volume receiving 45 Gy and 50 Gy was measured (V 45 and V 50). 
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7.OBSERVATIONS: 
7.1 DOSE TO BONE MARROW 
VOLUME OF BONE MARROW RECEIVING 10 Gy (V 10) AND VOLUME OF BONE 
MARROW RECEIVING 20 Gy (V 20) IN VARIOUS PLANS.  
 
Mean V10 in BMS-IMRT  = 89.58%       Mean V 20 in BMS-IMRT = 69.99% 
Table 2.1: V 10 and V 20 of bone marrow in various plans 
SL NO 4FB-
V10 
4FB-
V20 
3DCRT
-V10 
3DCRT-
V20 
IMRT-
V10 
IMRT-
V20 
BMSIMR
T-V10 
BMS1M
RT-V20 
1 95.59 91.59 97.05 92.06 98.49 83.46 87.93 67.32 
2 99.47 97.07 99.49 96.91 96.19 87.97 87.74 69.11 
3 95.97 91.31 95.88 90.94 95.6 81.92 83.12 54.71 
4 98.5 94.89 97.95 94.62 99.36 92.03 91.29 70.95 
5 100 99.7 99.99 99.63 100 93.95 92.05 72.91 
6 99.34 97.25 99.32 97.07 99.65 87.59 91.49 71.65 
7 99.19 96.33 99.36 95.93 96.5 87.83 92.14 70.08 
8 98.57 95.52 98.31 95.21 99.4 94.9 91.78 71.84 
9 96.1 92.07 96.06 92.09 99.55 83.48 86.39 69.17 
10 98.42 95.52 98.01 95.68 97.5 89.57 85.68 66.27 
11 99.66 98.52 99.56 98.5 99.04 96.95 94.91 74.44 
12 96.24 91.35 95.48 89.76 96.58 85.96 86.88 71.94 
13 98.08 94.99 98.15 95.27 98.36 89.97 91.75 75.45 
14 100 99.3 99.99 99.22 99.53 93.25 94.04 77.62 
15 98.98 96.32 98.88 96.26 97.57 82.16 86.63 66.92 
16 96.42 93.11 96.71 92.79 97.67 88.66 89.51 68.59 
MEAN  98.15 95.30 
 
  98.13 
 
  95.12 
 
  98.18 
 
  88.72 
 
  89.58 
 
    69.99 
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Fig .8.1: DVH curves of bone marrow in 4 FIELD BOX plan, 3DCRT, 
IMRT and BMS-IMRT for comparison of V10 AND V20 
 
   -WITH PELVIC BONE                        -WITHOUT PELVIC BONE 
                   - 4 FIELD BOX                                      - 3DCRT 
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AXIAL SECTIONS OF THE CT SCAN OF A REPRESENTATIVE PATIENT SHOWING 
100% ,70%,50% AND 40% ISODOSE LINES FOR BMS-IMRT,IMRT ,3DCRT AND 
4FIELD BOX 4 FIELD BOX TECHNIQUE 
 
 
 
     -CTV          -PTV         -100 % ISODOSE         -95%           -70%        - 50%          -40%IMRT: 
 
  Fig.9.1: Bone marrow sparing IMRT, 100%, 70%, 50% AND 40% 
isodose lines. 
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     -CTV          -PTV         -100 % ISODOSE         -95%           -70%        - 50%          -40% 
   Fig.9.2: IMRT plan showing 100%, 70%, 50% and 40% isodose lines. 
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Fig.9.3: 3DCRT plan showing 100%, 70%, 50% and 40% isodose lines. 
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 Fig.9.4:4 FIELD BOXplan showing 100%, 70%, 50% and 40% isodose 
lines. 
 
It was observed by visual inspection of the isodose curves that in BMS-IMRT plan ,there was 
a greater bending of the isodose curves away from the bone marrow, conforming the dose 
more closely to the PTV  in the regions were  bone marrow was contoured  when compared 
to the same isodose lines in IMRT,3DCRT and 4 field box 4 FIELD BOXtechnique. It was 
observed that IMRT plans were showing better sparing of the bone marrow when compared 
to 3DCRT and 4 field box 4 FIELD BOXtechniques. The observation noted for this lone 
patient was also seen in the average DVHs for all the 15 patients. 
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DOSE COLOUR WASH IN A REPRESENTATIVE PATIENT FOR ALL FOUR PLANS 
WITH BMS-IMRT, IMRT, 3DCRT AND 4 FIELD 4 FIELD BOX TECHNIQUES 
 
 
 
 
Fig.10.1: Dose colour wash in BMS –IMRT plan 
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                      Fig.10.2: Dose colour wash in IMRT plan 
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                     Fig.10.3: Dose colour wash in 3DCRT plan 
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                      Fig.10.4: Dose colour wash in 4 FIELD BOX plan 
 
Dose colour wash also gave similar representation of less doses to the bone marrow in BMS-
IMRT technique when compared to other techniques. But it was more appreciable in 
comparison between IMRT technique with 3DCRT and 4 field 4 FIELD BOX techniques. 
7.2 TARGET DOSE COVERAGE 
 
This was analyzed with the help of DVH curves, isodose lines and dose colour wash. 
ThePTV adequacy was evaluated by noting the corresponding D98 on the isodose curves . 
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DOSE VOLUME HISTOGRAM OF PLANNING TARGET VOLUME FOR THE 
AVERAGE DISTRIBUTION OF A REPRESENTATIVE PATIENT COMPARING BMS-
IMRT, IMRT,3DCRT AND MILC PLANNING. 
 
 
Fig.11.1: DVH curves of PTV for the average distribution of a 
representative patient in 4 FIELD BOX plan, 3DCRT, IMRT and BMS-
IMRT plan. 
 
              -4 FIELD BOX          -IMRT                -3DCRT            - BMS-IMRT 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
 
 
 
Sl no  4 field box 3D CRT IMRT BMS IMRT 
1  96.48 96.47 102.36 98.53 
2  95.37 97.50 99.89 96.60 
3  94.72 95.24 99.21 98.04 
4  95.27 95.20 98.90 98.50 
5  97.30 98.50 100 97.14 
6  98.20 97.23 98.80 97.67 
7  97.65 97.17 97.31 97.49 
8  97.38 96.06 98.95 96.70 
9  95.51 95.85 98.19 96.71 
10  95.78 95.33 101.10 99.20 
11  94.99 97.07 95.27 97.58 
12  97.58 98.75 95.59 99.79 
13  97.05 96.85 96.51 97.62 
14  95.78 95.63 99.63 96.69 
15  95.79 96.01 99.90 96.19 
16  93.63 95.51 99.34 98.64 
 
 
Table2. 3: Data set of PTV dose coverage(D 98 – in %) for 16 patients with 
4 field box , 3D CRT, IMRT and BMS IMRT plan 
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7.3 DOSE TO ORGANS AT RISK 
DOSE RECEIVED BY ORGANS AT RISK IN BMS-IMRT, IMRT, 3DCRT AND 4 FIELD 
BOX PLAN 
 
 
 
Fig.11.2: DVH curves for bowel of a representative patient in BMS-IMRT, 
IMRT, 3DCRTand 4 field boxplans. 
 
 
         -IMRT               -4 FIELD BOX               - BMS IMRT     - 3DCRT 
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Table 2.4: V45 ( in %) of bowel bag in 4 field box plan, 3D CRT , IMRT 
and BMS IMRT . 
SL NO  4 field box 3D CRT  IMRT  BMS IMRT 
1  23.98 28.07 23.14 19.19 
2  16.18 15.99 15.29 14.49 
3  18.01 18.50 13.67 11.84 
4  18.29 18.46 14.84 17.62 
5  20.34 19.25 14.31 13.70 
6  17.39 16.61 9.05 10.79 
7  7.27 6.64 5.32 4.45 
8  22.27 21.30 16.58 16.73 
9  15.48 16.43 10.69 9.85 
10  18.09 17.73 14.68 14.29 
11  35.92 35.03 21.34 23.56 
12  29.90 29.21 16.80 20.38 
13  6.77 7.38 5.05 3.89 
14  24.10 22.89 16.18 12.57 
15  28.03 28.21 21.91 17.18 
16  8.80 8.24 5.37 5.42 
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From the isodose curves itself it was evident that in IMRT and BMS-IMRT, as the 
prescription isodose curve and 95% isodose lines were conforming to the shape of the PTV, 
there was significant dose reduction to the bowelbag. According to the RTOG 0921 , volume 
of bowel bag receiving 45 Gy (V45)was documented for all the four plans for 15 patients. It 
was observed that there was significant reduction in volume of bowel bag receiving 45 Gy in 
BMS-IMRT and IMRT plans when compared to 3DCRT and 4 field box 4 FIELD BOX 
plans.3DCRT plans were superior over 4 field Box 4 FIELD BOX plans in sparing the bowel. 
 
     -BMS IMRT-IMRT- 4 FIELD BOX               -3DCRT 
  -LEFT FEMUR                -  RIGHT FEMUR 
 
Fig.11.3:  DVH curve for femoral head of a representative patient in   
BMS-IMRT, IMRT, 3DCRT and 4 field box plan. 
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SL NO   4 field box 3D CRT  IMRT  BMS IMRT  
  Rt Lt Rt Lt Rt Lt Rt Lt 
1  17.05 19.85 12.88 13.72 29.15 27.17 9.43 7.81 
2  16.87 23.26 16.57 23.01 19.40 3.66 5.24 5.29 
3  3.06 3.21 1.31 1.85 0.01 0.001 0.08 0.001 
4  6.73 6.91 6.20 6.34 5.05 6.16 3.37 4.38 
5  35.79 42.19 34.16 40.89 27.72 22.04 8.94 5.33 
6  9.62 8.82 9.02 8.19 7.51 6.21 0.80 2.33 
7  22.98 20.03 10.59 8.40 0.56 1.30 0.10 0.04 
8  97.51 92.30 97.55 91.71 7.37 7.40 12.71 16.95 
9  16.94 16.28 2.95 6.11 8.63 6.60 4.66 1.55 
10  4.62 2.55 0.24 0.04 2.27 2.50 0.08 0.009 
11  8.75 40.81 8.28 38.39 0.52 8.36 0.04 11.79 
12  25.53 28.88 28.06 31.69 2.02 2.21 7.68 8.69 
13  17.92 17.82 17.54 17.38 14.89 12.43 3.48 4.71 
14  20.45 20.67 19.79 20.59 16.53 13.36 0.66 1.28 
15  5.34 7.87 4.72 7.11 1.54 1.68 0.48 0.38 
16  10.22 11.84 10.03 12.07 1.23 2.21 1.61 2.93 
 
Table 2.5: V45( in %) of right and left femoral head with 4 field box plan, 
3D CRT, IMRT and BMS IMRT plan 
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       -IMRT      -4 FIELD BOX    - 3DCRT                 -BMS IMRT 
 
 
Fig.11.4:  DVH curve for bladder for a representative patient for BMS-
IMRT, IMRT, 3DCRT and 4field box technique. 
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SL 
NO 
 4 field box 3D CRT IMRT BMS IMRT 
1  88.94 90.16 73.13 66.99 
2  90.47 90.00 84.93 82.96 
3  99.74 100 99.12 95.07 
4  100 100 100 100 
5  98.80 99.02 86.80 75.18 
6  85.69 87.21 50.45 47.19 
7  95.55 90.62 88.20 88.72 
8  100 100 87.80 79.97 
9  81.10 87.60 79.64 89.08 
10  89.25 73.83 89.06 91.01 
11  90.73 90.78 78.99 82.31 
12  91.09 91.35 70.53 91.38 
13  92.25 91.95 70.85 59.50 
14  78.89 77.78 72.33 54.12 
15  81.57 82.25 78.01 63.76 
16  87.27 85.82 73.02 66.44 
 
Table2. 6: V45 (in %) of bladder in 4 field box plan , 3D CRT , IMRT and 
BMS IMRT plan 
 
-  
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- 4 FIELD BOX      - BMS-IMRT       -IMRT       -3DCRT                           
 
Fig.11.5:  DVH curve for rectum for a representative patient for BMS-
IMRT, IMRT, 3DCRT and 4 field box technique. 
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Sl no   4 field box 3D CRT  IMRT  BMS IMRT  
1  69.24 67.38 88.55 77.50 
2  72.68 72.80 80.27 78.29 
3  64.18 77.49 80.59 74.70 
4  89.75 90.40 91.70 89.45 
5  100 100 100 100 
6  98.52 99.24 100 98.37 
7  100 100 100 96.52 
8  97.10 98.58 67.02 55.99 
9  69.60 88.40 55.16 50.66 
10  41.33 99.91 100 99.95 
11  74.17 99.79 100 99.85 
12  97.53 98.63 70.84 97.13 
13  92.60 95.24 55.75 62.38 
14  60.33 92.85 99.20 77.54 
15  98.01 99.67 99 75.41 
16  58.31 74.22 92.46 90.45 
 
Table2.7: V50 ( in %) of rectum in 4 field box , 3D CRT , IMRT and BMS 
IMRT  plans  
 
 
As per the RTOG guidelines the bladder constrain is  V 45 < 35% and constrain to rectum is 
V 50 < 50%.It was observed in all the patients all four plans that these constrains are never 
achievable and these structures are  getting almost 100 % of the prescribed dose. This can be 
attributed to the fact that major portion of these structures were coming within the planning 
target volume to which the dose of 5040 cGy is prescribed. But since the maximum bladder 
tolerance dose is 80 Gy and that of rectum is 70 Gy the maximum point dose received by 
these structures during each plans can be documented and it can be considered during 
brachytherapy plan optimization later. 
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8.STATISTICAL ANALYSIS: 
 
BONE MARROW 
 
PLANS ACHIEVED NOT 
ACHIEVED 
TOTAL P Value 
 
 
 
 
.001 
 
4 FIELD BOX 0 
 
16 
 
16 
3DCRT 0 
 
16 
 
16 
IMRT 0 
 
  16 
 
16 
BMS IMRT 15 
(93.8%) 
1 
(6.3%) 
16 
(100%) 
 
 
Table 3.1: Tabularcolumn showing the number of cases andpercentage  in 
which bone marrow sparing could be achieved by different planning 
techniques 
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Fig 12.1: Bar diagram showing the number of cases in which bone marrow 
sparing could be achieved by different planning techniques. 
 
Fig 12.2:Pie diagram showing the % of patients for which BMS-IMRT 
could attain the constrain of V 10< 95% and V 20 < 76% 
0
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TARGET COVERAGE: 
 
 
Tabel 3.2: Tabular column showing the number of cases and percentage in 
which PTV constrains could be achieved by different planning techniques 
 
PLANS ACHIEVED NOT 
ACHIEVED 
TOTAL  P VALUE 
4 FIELD BOX 13 
 
(81.3%) 
3 
 
(18.8%) 
16 
 
(100%) 
 
 
 
 
 
 0.094 
3DCRT 16 0 16 
IMRT 16 0 16 
BMS IMRT 16 
 
0 
 
 
16 
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Fig 12.3: Bar diagram showing the number of cases in which adequate PTV 
coverage (  V 98> 95%, D 2 cc < 110%) could be achieved by different 
planning techniques. 
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OTHER ORGANS AT RISK: 
 
PLANS ACHIEVED NOT 
ACHIEVED 
TOTAL P VALUE 
4 FIELD BOX 13 
(81.3%) 
3 
(18.8%) 
16 
(100%) 
 
 
 
 
0.228 
3DCRT 13 
(81.3%) 
3 
(18.8%) 
16 
(100%) 
IMRT 15 
(93.8%) 
1 
(6.3%) 
16 
(100%) 
BMS IMRT 16 0 16 
 
 
 
Table 3.3: Tabularcolumn showing the number of cases and percentage in 
which the left femoral head constrains could be achieved by different 
planning techniques 
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Fig 12.4: Bar diagram showing the number of cases in which left femoral 
head constrain could be achieved by different planning techniques. 
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Table3.4: Tabularcolumn showing the number of cases and percentage in 
which the right femoral head constrains could be achieved by different 
planning techniques 
 
 
 
PLANS ACHIEVED NOT 
ACHIEVED 
TOTAL  P VALUE 
4 FIELD BOX 12 
(75%) 
4 
(25%) 
16 
(100%) 
 
 
 
 
0.027 
3DCRT 12 
(75%) 
4 
(25%) 
100% 
IMRT 100% 0% 100% 
BMS IMRT 100% 0% 100% 
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Fig 12.5: Bar diagram showing the number of cases in which right femoral 
head constrain could be achieved by different planning techniques 
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PLANS ACHIEVED NOT ACHIEVED TOTAL 
4 FIELD BOX 0 16 16 
3DCRT 0 16 16 
IMRT 0 16 16 
BMS IMRT 0 16 16 
 
 
 
 
 
Table3.5: Tabularcolumn showing the number of cases and percentage in 
which the bladder constrains could be achieved by different planning 
techniques 
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 Fig 12.6: Bar diagram showing the number of cases in which the bladder 
constrain could be achieved by different planning techniques 
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PLANS ACHIEVED NOT 
ACHIEVED 
TOTAL 
4 FIELD BOX 0 16 16 
3DCRT 0 16 16 
IMRT 0 16 16 
BMS IMRT 0 16 16 
 
 
Table 3.6: Tabularcolumn showing the number of cases and percentage in 
which the rectum constrains could be achieved by different planning 
techniques 
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Fig 12.7: Bar diagram showing the number of cases in which the rectum 
constrain could be achieved by different planning techniques 
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PLANS ACHIEVED NOT 
ACHIEVED 
TOTAL P VALUE 
4 FIELD 
BOX 
13 
(81.3%) 
3 
(18.8%) 
16  
 
 
 
 
 
 
0.027 
3DCRT 12 
(75%) 
4 
(25%) 
16 
IMRT 16 
(100%) 
 
 
0 
(0%) 
16 
BMS IMRT 16 
(100%) 
0 
(0%) 
16 
 
 
 
Table 3.7: Tabularcolumn showing the number of cases and percentage in 
which the bowel constrains could be achieved by different planning 
techniques 
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Fig 12.8: Bar diagram showing the number of cases in which the bowel bag 
constrain could be achieved by different planning techniques 
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 STATISTICAL ANALYSIS 
 
As per the aim of the study statistical analysis was done to analyse whether a bone marrow 
sparing IMRT plan can be made without compromising coverage to the target volume and 
without increasing dose to other organs at risk which are normally considered in ordinary 
plans. Analysis was made between 4 different treatment plans;4 FIELD BOX  plan, 3DCRT, 
IMRT and BMS –IMRT plans for all 16 patients. Chi-square test was used for statistical 
analysis. 
 
Statistical analysis for bone marrow. 
As per the earlier discussions the constrains for bone marrow were considered as V 10 < 95%  
and V 20 < 76%  as a value below these ranges have shown to  significantly reduce 
haematological toxicities. Out of the 16 plans with BMS IMRT, 15 plans were achieved with 
bone marrow dose well below the above constrains. This gave a 93.8% chance of  achieving 
this constrain with a p value of .001.None of the remaining plans , even with ordinary IMRT 
plans could achieve the prescribed constrain. The case of BMS –IMRT which could not 
achieve the constrain had V10=94.04% (within normal limit) and  V 20= 77.62%. This value 
of 77.62% for V20 with BMS-IMRT was well below and near normal to the constrain( V 20< 
76%) when compared to  other three plans( 4 FIELD BOX V20= 99.30%,  3DCRT  V 
20=99.22%and IMRT V20=93.25%) . 
Statistical analysis of target volume coverage 
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As per the protocol, the adequate target coverage was analysed  by evaluating whether D 98> 
95% and D 2cc < 110% of the prescribed dose. These  parameters were considered in all 4 
plans for all the 16 patients. Out of 16 patients all of these constrains were achieved together 
in 13/ 16 patients with 4 FIELD BOX plan, 16/16 patients with 3DCRT, 16/16 patients with 
IMRT and 16/16 patients with BMS-IMRT.  
Statistical analysis of other organs at risk 
 
Femoral head 
 
The femoral head was drawn as two separate structure, right  and left femoral head . The 
constrain considered for femoral head was V 45 < 25%.V 45 was measured for all the plans 
for all 16 patients. In case of right femoral head, the constrains could be achieved for 13/16 
patients with 4 FIELD BOX plan, 13/16 patients with 3DCRT plan, 15/16 patients with 
IMRT plan a 16/16 patients with BMS –IMRT plan. Hence BMS-IMRT was found to be 
superior over other plans in achieving the femoral head dose constrain.  
 
In case of left femoral head, it was observed that the constrain was attained for 12/16 patients 
with 4 FIELD BOX, 12/16 patients for 3DCRT, 16/16 patients with IMRT and 16/16 patients 
with BMS –IMRT. From these observations it can be concluded that BMS –IMRT is equally 
beneficial as IMRT over decreasing dose to the femoral head well below the dose constrains. 
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Bowel bag 
The  constrain given to the entire bowel bag was V45< 25%.It was measured for all the plans 
for all 16 patients.Theconstrains  could be achieved for 13/16 patients with 4 FIELD BOX 
plan, 12/16 patients with 3DCRT plan, 16/16 patients with IMRT plan an 16/16 patients with 
BMS –IMRT plan. 
Bladder 
The  dose constrain considered for bladder was  V 45< 35%.As mentioned earlier , as most of 
the portion of the bladder was within the planning target volume in carcinoma cervix 
treatment planning this constrain was never achievable. In order to show that BMS –IMRT is 
not inferior to other plans when the bladder dose is considered, V 45 for all the 16 patients in 
all the 4 plans was noted. It was observed that 0/16 patients achieved the dose constrain for 
bladder in 4 FIELD BOX, 3DCRT, IMRT and BMS-IMRT plan. 
Statistical analysis for Rectum 
The dose constrain to the rectum was V 50 <50%.Similar to the observation for bladder ,as 
most of the portion of the rectum  is involved within the planning target volume , this 
constrain was never achievable. V 50 for all the 16 patients in all the 4 plans was noted. It 
was observed that 0/16 patients achieved the dose constrain for bladder in 4 FIELD BOX, 
3DCRT, IMRT and BMS-IMRT plan.BMS –IMRT was hence proved non inferior to other 
plans in toxicity to rectum. 
Maximum dose to the rectum was measured. No hot spots were noted within the rectal 
volume.  
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9.DISCUSSION 
 
The current standard of care in patients diagnosed with locally advanced carcinoma cervix is 
concurrent chemo irradiation. Over the past many decades, the radiation delivery  technique 
evolved with an aim to reduce the toxicity to the normal structures without compromising the 
dose to the target volume .Majority of the earlier studies emphasised decreasing the dose to 
bowel , bladder and rectal toxicities. Later, clinicians started observing that haematological 
toxicity is also a matter of concern in patients undergoing chemo irradiation which resulted in 
delayed  treatment and subsequently  decreased survival . This paved way to various studies 
in which bone marrow was considered as a separate organ at risk with a dose constrain. Rose 
et al came up with the observation that V10 and V20 of the bone marrow ( volume of bone 
marrow receiving 10 Gy and 20 Gy respectively) influences grade 3 and grade 4 
hematological toxicity (54). 
This wasa dosimetric study on data set from 16 women diagnosed with carcinoma cervix and  
treated in our institution from July 2013 to  January 2014 using 3D CRT or IMRT. For all of 
the 16 patients 4 plans, BMS- IMRT, IMRT , 3D CRT and four field box technique were 
modelled. The aim of this study was to analyse whether a bone marrow sparing IMRT plan 
could be achieved without compromising coverage to the target volume and without 
increasing dose to other organs at risk. BMS - IMRT planningalgorithm was similar to IMRT 
plans,except that in BMS-IMRT  the bone marrow was contoured and given dose constrain.It 
was observed that it is feasible to achieve a BMS-IMRT plan without compromising the 
target coverage and without increasing the dose to other organs at risk.The mean V10 and 
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V20 to bone marrowin our study was 89.58%  and  69.99%and was comparable to the mean 
doses of 95% and 76% as reported by Rose et al (50) 
 
Eventhough this dosimetric study focused on carcinoma cervix patients, this modality can be 
beneficial in reducing marrow toxicity in pelvic malignancies like rectum  and anal canal 
where adjuvant treatment also plays a significant role(55).It may be of significant benefit as 
these patient are subjected to further insult to their marrow by undergoing systemic 
chemotherapy Another group who may benefit from this study are the patients who are 
diagnosed to have  lymphomas on combined modality  treatment with consolidation pelvic 
radiation therapy following chemotherapy and stem cell rescue(56). 
 
The main drawback of this study was,that it was a dosimetric study with no clinical 
correlation  between the percentage reduction of dose to the bone marrow and its effect on 
blood parameters which helps in quantifying haematological toxicity.Another drawback of 
this study was the non availability of a universally accepted contouring consensus guidelines 
for bone marrow and imaging technique which can be used for the same. In the light of 
various studies done by the pioneers in BMS-IMRT(54) , the entire medullary cavity was 
contoured as a surrogate of the active bone marrow. As the red bone marrow is involved in 
active haematopoiesis and yellow marrow is predominantly fat, this method of contouring the 
entire bone outside the cortex can be quite inaccurate. 
Inorder to overcome this ,various studies have come up now incorporating  functional scan 
like PET CT or MRI which gives a better representation of bone marrow than CT   into the 
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IMRT planning(53).These studies are still under way and no robust data is available .The 
accurate SUV value which represent the active part of bone marrow is also under evaluation. 
In theIndian scenario where majority of the patients are of low socio economic status and  
even the access to state basic health care is limited , incorporating PET CT or even MRI to 
the treatment planning for bone marrow sparing  in routine practice may not be a feasible 
option . In such a situation CT scan may be a better surrogate  option over PET CT or MRI in 
a limited resource setting. While the optimal way to dilineate bone marrow is still evolving , 
there is strong evidence which is emerging that Bone marrow sparing IMRT 
significantlyreduces the dose to Bone marrow and hence reduce haematological toxicity. 
Though not yet ready to be considered as a standard of care Bone Marrow sparing IMRT 
should be   considered in appropriate patients. 
 
 
10.CONCLUSION 
 
Bone Marrow Sparing IMRT is a feasible option for the management of locally advanced 
carcinoma cervix as it helps in reducing the dose received by the bone marrow without 
compromising the planning target volume coverage and without increasing the dose to other 
normalorgans at risk.However the clinical benefit needs to be evaluated in a prospective 
clinical trial 
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